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ABSTRACT 
 
Eric M. Wauson:  The Regulation of Carbamoyl Phosphate Synthetase-Aspartate 
Transcarbamoylase-Dihydroorotase (CAD) by Phosphorylation and Protein-Protein 
Interactions 
(Under the direction of Lee M. Graves, Ph.D.) 
 
Pyrimidines have many important roles in cellular physiology, as they are used in 
the formation of DNA, RNA, phospholipids, and pyrimidine sugars.  The first rate-
limiting step in the de novo pyrimidine synthesis pathway is catalyzed by the carbamoyl 
phosphate synthetase II (CPSase II) part of the multienzymatic complex Carbamoyl 
phosphate synthetase, Aspartate transcarbamoylase, Dihydroorotase (CAD).  CAD gene 
induction is highly correlated to cell proliferation.  Additionally, CAD is allosterically 
inhibited or activated by uridine triphosphate (UTP) or phosphoribosyl pyrophosphate 
(PRPP), respectively.  The phosphorylation of CAD by PKA and ERK has been reported 
to modulate the response of CAD to allosteric modulators.  While there has been much 
speculation on the identity of CAD phosphorylation sites, no definitive identification of 
in vivo CAD phosphorylation sites has been performed.  Therefore, we sought to 
determine the specific CAD residues phosphorylated by ERK and PKA in intact cells.  
We observed the PKA-induced phosphorylation of Ser1406 and Ser1859 HEK-293 cells.  
Surprisingly, while ERK phosphorylated CAD on multiple residues in vitro, CAD was 
not an ERK substrate in HEK-293 cells.  We determined the identity of a previously 
unknown phosphopeptide in CAD isolated from HEK-293 cells.  We also observed that 
the phosphorylation of CAD in HEK-293 cells is important for the maintenance of 
iv
CPSase II activity.  In addition to investigating the regulation of CAD by 
phosphorylation, we have identified a novel protein-protein interaction between CAD and 
the human cell cycle checkpoint protein hRad9.  The interaction was mapped to the 
CPSase II portion of CAD, and the binding of hRad9 to CAD induced a significant 
activation of CPSase II activity.  Taken together, these studies demonstrate novel 
mechanisms of CAD regulation in mammalian cells. 
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CHAPTER I 
 
GENERAL INTRODUCTION 
21.1    Significance 
The pyrimidines cytosine, uracil, and thymine are the heterocylic aromatic 
nitrogenous bases that, when attached to ribose sugars, compose the pyrimidine 
nucleosides cytidine, uridine, and thymidine, respectively.  When these nucleosides 
contain one, two, or three phosphate groups, they are referred to as pyrimidine 
nucleotides.  In addition to being the basic building blocks for RNA and DNA, 
pyrimidine nucleotides also are used in the synthesis of numerous other cellular 
components including glycoproteins, glycolipids, and phospholipids.  Additionally, 
uridine nucleotides can function as ligands for cell surface receptors, as discussed below.  
Furthermore, pyrimidine nucleotides can exert anti-apoptotic effects by binding to 
cytochrome C, and thereby inhibiting apoptosome formation (Chandra et al., 2006). 
The nucleotide uridine triphosphate (UTP) is incorporated directly into the synthesis 
of RNA polymers, or used as a substrate in the synthesis of cytidine triphosphate (CTP).  
Uridine diphosphate (UDP) is a substrate for ribonucleotide reductase (RNR), which 
forms deoxyuridine diphosphate (dUDP).  The cell then converts dUDP to 
deoxythymidine triphosphate (dTTP), a necessary molecule for DNA synthesis (Figure 
1.1).  Additionally, UTP is used in the synthesis of UDP-glucose and UDP-N-
acetylglucosamine.  These UDP-sugars are used in the glycosylation of proteins and the 
formation of UDP-sugar derivatives, which are substrates for the synthesis of 
disaccharides and polysaccharides such as glycogen.  Furthermore, UDP can be 
converted to uridine triphosphate (UTP) by nucleoside diphosphate kinase (Reviewed in 
(Huang and Graves, 2003). 
3Uridine nucleotides and UDP-sugars function as ligands for numerous members 
of the G-protein coupled P2Y receptors.  Signaling through these receptors has been 
reported to elicit diverse physiological consequences, such as the induction of chemotaxis 
in dendritic cells (Idzko et al., 2002), the vasodilation or vasoconstriction of blood vessels 
(reviewed in Brunschweiger and Muller, 2006), and the enhanced proliferation of human 
neural stem precursor cells (Milosevic et al., 2006).  Hence, the biosynthesis of 
pyrimidine nucleotides may influence cell signaling through the regulation of these 
receptors. 
The cytidine nucleotides (CTP and dCTP) are incorporated into both RNA and 
DNA polymers.  Additionally, CTP is a substrate for the formation of cytidine 
diphosphate-lipids (CDP-lipids), which are used by cells to make phospholipids.  
Phospholipids are important components of cellular membranes and act as second 
messengers.  Moreover, cytidine monophosphate (CMP) is used in the synthesis of sialic 
acid.  Sialic acids are nine carbon sugars, which are commonly attached to the ends of 
glycoproteins.  Some of the functions of sialic acids have been elucidated, including the 
creation of recognition signals on receptors for sugar binding protein ligands, such as the 
selectins and various interleukins.  Additionally, sialic acids form the most commonly 
found ligands for receptors on pathogenic viruses, bacteria, and protozoa (reviewed in 
Lehmann et al., 2006; Schauer, 2000).   
Mammals obtain pyrimidine nucleotides by either de novo synthesis from basic 
cellular molecules including ATP, glutamine, and bicarbonate, or through an alternative 
salvage pathway that uses the nucleosides uridine and cytidine to make pyrimidine 
nucleotides.  The relative importance of these two pathways is dependent on the cell type 
4and physiological state, but in general, slower growing or quiescent cells tend to rely on 
salvage synthesis of pyrimidines, while rapidly growing cells, such as mitogen-stimulated 
lymphocytes, require the de novo synthesis of pyrimidines (Ruckemann et al., 1998).  
Since the salvage and de novo synthesis pathways both form UMP, this is the point of 
convergence between these two pathways.  UMP is the common precursor for all other 
pyrimidine nucleotides.  UDP and UTP can be formed by the phosphorylation of UMP by 
UMP kinase and the phosphorylation of UDP by nucleoside diphosphate kinase.  CTP is 
formed when CTP-synthetase transfers the amide from glutamine and transfers it to UTP 
(Figure 1.1) (reviewed in Huang and Graves, 2003). 
1.2.    Salvage pyrimidine synthesis 
A major source of uridine and cytidine for the salvage synthesis of pyrimidine 
nucleotides is the degradation of nucleic acids and nucleotides.  An important class of 
enzymes involved with the degradation of UTP, UDP, and UMP into uridine is the 5-
nucleotidases.  Cytidine is converted to uridine by the action of cytidine deaminase.  The 
catabolism of uridine and uracil is accomplished by the activities of uridine 
phosphorylase and dihydropyrimidine dehydrogenase, which catalyze the conversion of 
uridine to uracil and uracil to dihydrouracil, respectively (reviewed in Anderson and 
Parkinson, 1997).  In most tissues, uridine is the starting point for the pyrimidine salvage 
pathway.   The human blood plasma levels of uridine are strictly regulated at 3-5 µM, and 
the liver functions to keep this level constant by either degrading or synthesizing uridine 
as the need arises (reviewed in Connolly and Duley, 1999; Traut, 1994).   
The uridine and cytidine in the blood plasma and other extracellular fluids are 
transported across cellular membranes by nucleoside transporters.  These transporters are 
5critical homeostatic regulators of intra- and extracellular concentrations of nucleosides 
and nucleotides.  The two major families of nucleoside transporters identified in 
numerous species, including mammals, are the equilibrative (sodium-independent) 
nucleoside transporters (ENTs) and the concentrative (sodium-dependent) nucleoside 
transporters (CNTs) (reviewed in Zhang et al., 2007).  Increased ENT expression is 
highly correlated with rapid cellular proliferation, and the mitogen stimulation of 
lymphocytes causes a significant increase in ENT expression (Smith et al., 1989; Wiley 
et al., 1989).  Once uridine or cytidine is transported into cells, uridine/cytidine kinase 
(UCK) phosphorylates them creating UMP and CMP.  The activity of UCK, which has 
been reported to be the rate-limiting step in the salvage synthesis of pyrimidines, can be 
increased by serum growth factors and insulin.  Furthermore, UCK activity is 
significantly elevated in various tumor cell models (reviewed in Huang and Graves, 
2003). 
1.3    De Novo pyrimidine synthesis  
 De novo pyrimidine synthesis is a cellular process where glutamine, ATP, 
bicarbonate and aspartate are converted to uridine monophosphate by three proteins 
containing six enzymatic activities (Figure 1.2).  The multifunctional protein CAD 
catalyzes the first three reactions in this pathway.  CAD is an acronym derived from the 
three enzymatic activities contained within this protein:  Carbamoyl phosphate synthetase 
II (CPSase-II)-Aspartate transcarbamoylase (ATCase)-Dihydroorotase (DHOase).  
CPSase-II is the rate-limiting step in the de novo pyrimidine synthesis pathway, and is 
highly regulated by multiple mechanisms (Figure 1.5.).  Dihydroorotate, the final product 
created by CAD, is thought to diffuse through the cytoplasm to the mitochondria where it 
6serves as a substrate for the fourth enzyme in the de novo pyrimidine synthesis pathway 
dihydroorotate dehydrogenase (DHODH) (reviewed in Jones, 1980).  
 DHODH is a mitochondrial integral membrane protein that catalyzes the 
oxidation of dihydroorotate (DHO) to orotate.  Since electrons released during the 
oxidation of DHO are transferred to ubiquinone, DHODH is an important component of 
the mitochondrial respiratory chain (Loffler et al., 1997).  The interrelatedness of 
pyrimidine synthesis and cellular respiration was nicely demonstrated when chemically 
induced respiratory chain dysfunction was shown to inhibit DHODH activity causing a 
reduction in de novo pyrimidine synthesis (Beuneu et al., 2000; Gattermann et al., 2004).  
DHODH is a relevant drug target, since it was observed by Simmonds and colleagues 
that the DHODH inhibitor leflunomide (Arava) prevented mitogen-induced lymphocyte 
expansion.  Leflunomide is currently being used clinically as an immune suppressant in 
the treatment of rheumatoid arthritis (reviewed in Herrmann et al., 2000).    
 The final two steps in de novo pyrimidine biosynthesis are catalyzed in the 
cytoplasm by the bifunctional enzyme UMP-synthetase.  The mammalian protein consists 
of the orotate phosphoribosyltransferase domain, which catalyzes the transfer of the 
phosphoribosyl group of 5-phosphoribosyl 1- pyrophosphate (PRPP) to orotate creating 
OMP, and the orotidine-5-phosphate decarboxylase domain, which catalyses the 
formation of UMP from OMP (reviewed in (Evans and Guy, 2004; Jones, 1980).    
 Early studies demonstrated that UMP-synthetase formed dimers in the presence of 
OMP, leading to an increase in enzymatic activity (Traut and Jones, 1977).  The activity  
of UMP-synthetase was observed to be elevated in rapidly dividing cells, such as 
regenerating liver cells (Pausch et al., 1972) or murine leukemia cells (Reyes and 
7Guganig, 1975).  Furthermore, a study performed by Mitchell and Hoogenraad 
demonstrated the activity profile of the orotate phosphoribosyl transferase activity of 
UMP-synthetase in synchronized rate hepatoma cells that were induced to enter the cell 
cycle.  They observed that activity of this enzyme was low in G1, rose rapidly during S-
phase, but declined rapidly during the G2/M phase (Mitchell and Hoogenraad, 1975).       
1.4    CAD 
1.4.1    Enzymatic Domains in CAD and Mechanisms of Reactions 
 While early research demonstrated that the three enzymatic reactions that CAD 
performed were present in mammalian cells, it was not until 1970 that Jones speculated 
that these enzymes might be combined in one polypeptide chain (Jones, 1970).  This 
speculation was based on genetic data that demonstrated that a single protein in 
Neurospora and yeast had both ATCase and CPSase enzymatic activities.  Subsequent 
experiments demonstrated that the CPSase and ATCase enzymatic activities were 
contained within single complexes in Ehrlich ascites cells, mouse spleen, human 
lymphocytes (Hoogenraad et al., 1971; Ito and Uchino, 1973; Shoaf and Jones, 1971; 
Shoaf and Jones, 1973).  Finally, in 1977, Stark and colleagues demonstrated that the 
CPSase, ATCase, and DHOase activities were on a single, approximately 220,000 dalton 
protein by isolating CAD from a hamster cell line that was induced to overexpress all 
three enzymatic activities (Coleman et al., 1977).   
1.4.1.a    CPSase II 
 Brzozowski and colleagues first purified the bacterial CPSase from E. coli in 
1966, and enzymatic data suggested that CPS catalyzed multiple steps during the 
formation of carbamoyl phosphate (Kalman et al., 1965).    The E. coli CPSase enzyme 
8was determined to consist of a small subunit that liberated ammonia from glutamine and 
transferred it to the large subunit where the formation of carbamoyl phosphate occurred 
(Trotta et al., 1974).  Both subunits had significant amino acid sequence homology with 
the large subunit of the E. coli CPSase (Simmer et al., 1990a), and much of what we 
know about the reaction mechanisms of the synthetase regions of CPSase II was derived 
from studies designed to investigate the E. coli CPSase.   
 The N-terminal section of the CPSase II domain of CAD contains the GLNase 
subdomain, and its sequence is highly similar to the sequence of the small subunit of E. 
coli CPSase (Simmer et al., 1990b).  The GLNase subdomain is linked to the CPS.A and 
CPS.B subdomains by a 29-amino acid segment (Figure 1.3) (Bein et al., 1991; Maley 
and Davidson, 1988; Simmer et al., 1990a).  Numerous studies suggest that the catalytic 
mechanism of GLNase is similar to cysteine proteases in that a nucleophilic histidine 
residue removes a proton from the sulfhydryl group of a cysteine residue in the active 
site.  This cysteine residue then forms a -glutamyl thioester intermediate with glutamine 
and the subsequent release of ammonia occurs.  Finally, in the rate limiting step, the 
thioester is hydrolyzed causing the regeneration of the active form of GLNase (Chaparian 
and Evans, 1991; Miran et al., 1991; Wellner et al., 1973).   
 When the hamster GLNase subdomain of CPSase II was cloned, expressed, and 
purified from E. coli, it was observed to have minimal glutaminase activity by itself.  
However, the activity was increased to normal levels when the GLNase subdomain was 
mixed with the E. coli CPSase large subunit (which is highly similar in sequence with the 
CPS.A and CPS. B subdomains of CPSase II) suggesting a functional linkage between 
the two subdomains (Guy and Evans, 1994b).  Furthermore, Evans and colleagues 
9demonstrated that the GLNase activity of CAD was significantly lowered when ATP and 
HCO3-, the substrates for the CPS.A and CPS.B subdomains, are absent.  Therefore, the 
authors hypothesized that the linkage of these domains allowed for a synchronization 
between the GLNase activity and the CPS.A and CPS.B. activities, allowing for the 
efficient use of substrates (Hewagama et al., 1999). 
 The large subunit of E. coli CPSase corresponds to the CPS (A) and CPS (B) 
subdomains of CAD (CPSase II synthetase regions) (Figure 1.3).  Powers and Meister 
determined that the E. coli CPSase bound 2 molecules of ATP at two separate active sites 
where the formation of the unstable intermediates, carboxy phosphate and carbamate 
were synthesized (Powers et al., 1977; Powers and Meister, 1978).  Numerous 
biochemical studies have contributed to the elucidation of the catalytic mechanism of E. 
coli CPSase.  As described above, there are three active sites contained within the CPSase 
complex.  The first active site is located within the small subunit, and is where glutamine 
is hydrolyzed to liberate ammonia molecules.  The second active site, which is located 
within the CPS.A region of the large subunit, phosphorylates bicarbonate, creating 
carboxyphosphate.  Carbamate then is formed from ammonia via a nucleophilic attack on 
the carboxyphosphate intermediate.  Finally, the third active site, located in subdomain B 
(CPS.B), catalyzes the formation of carbamoyl phosphate by phosphorylating carbamate 
(Reviewed in Holden et al., 1999).  Studies using positional isotope exchange 
demonstrated that the kinetic reaction mechanisms of the CPSase II of mammalian CAD 
were similar to the reaction mechanisms of E. coli CPSase (Meek et al., 1987). 
 Since the half-lives of carboxyphosphate and carbamate at neutral pH are quite 
short, the synchronization of the three reactions catalyzed by CPSase is important for the 
10
efficient use of these unstable intermediates.  It was demonstrated that the initiation event 
of the CPSase reaction cascade was the phosphorylation of bicarbonate at the second 
active site in the CPS.A region.  This event caused a conformational change to the first 
active site in the small subunit; thereby, inducing a significant increase in the rate of 
glutamine hydrolysis.  This ensures that there is ammonia immediately available to react 
with carboxyphosphate to form carbamate (Miles and Raushel, 2000). 
 The crystal structure of the E. coli CPSase was solved and found to consist of 
heterotetramer of the small and large CPSase subunits.  Analysis of the crystal structure 
demonstrated the existence of a molecular tunnel in the interior of the protein that 
allowed unstable ammonia, carboxyphosphate, and carbamate to be channeled from the 
first through the third active site over a distance of approximately 100 angstroms (Thoden 
et al., 1997).  Evidence supporting the hypothesis that the molecular tunnel allowed the 
channeling of intermediates was demonstrated by measuring CPSase enzymatic 
parameters in enzymes that had holes and blockages engineered into different points 
along the length of the tunnel (Huang and Raushel, 2000a; Huang and Raushel, 2000b; 
Kim et al., 2002; Kim and Raushel, 2004). 
1.4.1.b    ATCase and DHOase 
 The carbamoyl phosphate that is formed by the CPSase II domain is used by the 
ATCase domain of CAD to form carbamoyl aspartate.  The approximately 40, 000 dalton 
fully active ATCase domain was isolated from hamster CAD elastase digests (Grayson 
and Evans, 1983).  Subsequent experiments demonstrated that the ATCase domain had a 
molecular weight of 34,323 daltons, and its sequence was highly homologous with the 
sequence of the E. coli ATCase (Simmer et al., 1989).  Studies on the E. coli ATCase 
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have suggested that the binding of carbamoyl phosphate occurs first, followed by 
aspartate (Porter et al., 1969).  Furthermore, additional reports suggested that the binding 
of carbamoyl phosphate induced a conformational change in both E. coli ATCase and the 
ATCase domain of CAD, which was necessary for the subsequent binding of aspartate 
(Porter et al., 1969; Qiu and Davidson, 2000). While the E. coli ATCase is allosterically 
regulated by ATP, CTP, and UTP, the ATCase domain of CAD is not regulated by 
allosteric effectors (reviewed in Evans and Guy, 2004; Lipscomb, 1994).  
 The carbamoyl aspartate synthesized by the ATCase domain of CAD is used as a 
substrate by the DHOase domain to catalyze the reversible formation of dihydroorotate.   
Early work by Christopherson and Jones on the mouse DHOase suggested that the 
catalytic mechanism involved a zinc ion and a histidine residue (Christopherson et al., 
1979).   Evans and colleagues determined that the 44,000 dalton DHOase region of CAD 
was folded into an autonomously functioning domain when they excised DHOase from 
CAD by treating with elastase.  It was determined that the isolated DHOase domain 
formed homodimers in solution.  Furthermore, atomic absorption spectroscopy confirmed 
that each DHOase subunit contained a single zinc ion.  (Kelly et al., 1986).   
 The crystal structure of the E. coli ATCase was solved and the active enzyme 
was determined to consist of two catalytic trimers in complex with three regulatory 
dimers (Stevens et al., 1991).  The crystal structure of the E. coli DHOase demonstrated 
the existence of two catalytic zinc ions, while, as described above, the DHOase of CAD 
only has one zinc ion per subunit.  While the crystal structure of the DHOase domain of 
CAD has yet to be solved, Christopherson and colleagues have grown and analyzed 
crystals of this domain (Maher et al., 2003). 
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1.4.2    CAD Enzymatic Properties and Structure 
 Studies using controlled proteolysis, and the cloning and expression of the 
separate domains of CAD have demonstrated that each of the three domains in CAD can 
exist as separately folded autonomously functional enzymes.  Furthermore, these 
experiments allowed for the elucidation of the order of the domains in CAD polypeptide, 
which is as follows:  NH2-CPSase II-DHOase-ATCase-COOH (Kim et al., 1992; 
Williams et al., 1990). 
 The discretely folded functional domains of CAD are linked by interdomain 
linker regions.  The length of the linker region that connects the DHOase and ATCase 
domains (DA linker) is conserved in all eukaryotes (Figure 1.3). Studies by Guy and 
Evans demonstrated that while DA linker deletion mutants of CAD had kinetic 
parameters similar to wild-type CAD, there was a reduced thermal stability of CPSase II 
activity.  Additionally, it was observed that exogenously added carbamoyl phosphate 
could dilute the carbamoyl phosphate made by CPSase II to a much greater extent in the 
DA linker deletion mutant of CAD when compared to wild-type CAD.  Therefore, it 
appeared that the DA linker facilitates carbamoyl phosphate channeling and enzyme 
stability (Guy and Evans, 1994a; Guy and Evans, 1994c).   
 Stark and colleagues observed that most of the CAD in cells was composed of 
trimers and hexamers of the 243-kDa polypeptide (Coleman et al., 1977).  Crosslinking 
studies done by Evans and colleagues demonstrated that CAD monomers gradually 
formed cyclic hexamers with open planar appearances and that a portion of these 
hexamers formed larger oligomeric structures possibly representing the association of 
hexamers (Lee et al., 1985).  Additional studies demonstrated that the hamster CAD 
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residues Asp2009 and Arg2187, which are located in the ATCase domain (Figure 1.3), were 
critical for the formation of CAD hexamers. The site-directed mutagenesis of these 
residues to alanines caused a significant reduction in the Vmax of ATCase, suggesting that, 
like the E. coli ATCase, oligomerization of this enzyme was important for catalytic 
activity. 
 All CAD substrates were observed to have Michaelis-Menten kinetics and the 
apparent affinity of each of the substrates was determined by Christopherson and Jones.  
The CPSase II activity was demonstrated to be the slowest of the three enzymes as the 
maximum velocities for CPSase II, ATCase, and DHOase were observed to be 329, 
18,600 and 2,910 (pmol/min/µg), respectively (Christopherson and Jones, 1980).    
 The activity of CPSase II is unstable in aqueous buffers, and the addition of 
dimethylsulfoxide (DMSO) and glycerol was shown to stabilize this enzyme during 
storage and assay conditions (reviewed in Jones, 1980).  A study by Tatibana and 
colleagues demonstrated that DMSO actually decreased the apparent Km for MgATP 
(Ishida et al., 1977).  Therefore, since DMSO is commonly used in CAD activity assays, 
the DMSO concentration should be noted when trying to compare the kinetic parameters 
of CAD between separate studies. 
1.4.2.a    Allosteric regulation of CAD 
 CPSase is the rate-limiting step of de novo pyrimidine biosynthesis and is 
allosterically regulated in all organisms tested.   However, since the E. coli CPSase is 
used in both pyrimidine and arginine synthesis, and the CPSase II in animals is involved 
solely in pyrimidine synthesis, the two enzymes have evolved to use different regulatory 
ligands.  The E. coli enzyme is activated by NH3, IMP, and ornithine and inhibited by 
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UMP, while the mammalian CPSase II is inhibited by UTP, UDP, UDP-glucose, CTP, 
dUDP, and dUTP and activated by PRPP.  The allosteric ligands activate or inhibit 
CPSase II activity by decreasing or increasing the affinity of the enzyme for ATP 
respectively.  Furthermore, the polyamines spermine and spermidine inhibit the PRPP-
induced increase in CAD activity  (reviewed in Jones, 1980).     
 It was determined by Rubio and colleagues that UMP was bound to a 20-kDa 
fragment on the C-terminus of E. coli CPSase (Cervera et al., 1996).  To determine if this 
regulatory domain region of E. coli corresponded to the homologous region in CPSase II 
of CAD, Evans and colleagues created an E. coli/hamster chimeric CPSase that consisted 
of most of the E. coli CPSase, except that the 20-kDa regulatory domain (B3 subdomain) 
was replaced with the homologous hamster CPSase II region. Interestingly, this chimera 
became insensitive to UMP and IMP, but was now able to be modulated with PRPP and 
UTP.  Therefore, it was concluded that both PRPP and UTP bound in the CAD B3 
subdomain (amino acids 1265-1461) (Figure 1.3) (Liu et al., 1994).  By using the crystal 
structure to make predictions about the CPSase II domain of mammalian CAD, Davidson 
and colleagues performed site-directed mutagenesis studies that demonstrated that both 
PRPP and UTP could bind in a noncompetitive manner to the B3 subdomain.  
Furthermore, it appeared that PRPP activation dominates when both allosteric effectors 
were bound simultaneously (Simmons et al., 2004). 
 Cellular levels of PRPP can have significant effects on pyrimidine metabolism as 
it is used both as a substrate for UMP-synthetase, and as an allosteric activator of 
CPSase.  PRPP synthetase catalyzes the formation of PRPP from ribose-5-phosphate and 
ATP.  The average cellular concentration of PRPP was reported to be 0.1 mM (Jones, 
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1980), but fluctuations in this level can be caused by perturbations of ribose-5-phosphate 
levels and mitogens, such as insulin and epidermal growth factor (EGF), which induced 
an increase in PRPP-synthetase activity (Ishijima et al., 1988).  Furthermore, Brand and 
colleagues demonstrated that PRPP levels increased through the G1-phase and reached 
maximum levels in the S-phase of concanavalin A stimulated rat thymocytes (Schobitz et 
al., 1991). 
 The allosteric regulation of CAD has been observed to be modified by both CAD 
phosphorylation (as discussed below) and a single point mutant discovered in the 
Drosophila melanogaster CAD gene rudimentary (r).  The Drosophila black (b) mutation 
causes a dark cuticle color, a phenotype that is thought to be caused by lowered 
concentrations of -alanine due to an abnormal increase in the catabolic enzyme -
alanine transaminase.  The suppressor of black (rsub(b)) mutation, which is found within 
the r gene, causes the dark cuticle phenotype of the (b) mutation to be restored to the 
normal color.  Davidson and colleagues demonstrated that (rsub(b)) phenotype was caused 
by the Glu1153 to Lys1153  (numbers represent corresponding residues in hamster CAD) 
(E1153K) mutation in the CPS.B2 domain of CAD (Figure1.4).  It was further 
demonstrated that the E1153K mutation caused a significant reduction in the UTP-
induced inhibition of CPSase II activity without affecting other enzymatic parameters 
(Simmons et al., 1999). 
 Carrey and colleagues have proposed that in addition to the allosteric regulation 
of CAD induced by PRPP and UTP, there exists a reciprocal allosteric mechanism that 
allows the substrates of CPSase II to activate ATCase and the substrates for ATCase to 
activate CPSase II. The binding of aspartate to ATCase caused CPSase II to be less 
16
inhibited by its product carbamoyl phosphate.  Furthermore, the binding of substrates to  
CPSase II caused an increase in the affinity ATCase for carbamoyl phosphate and 
aspartate.  It was proposed reciprocal allostery evolved to increase the efficient use of the 
unstable substrate intermediates during the passage between active sites in CAD (Irvine 
et al., 1997). 
1.5    CAD Evolution 
 While the first three steps in the de novo pyrimidine synthetic pathway are 
identical in bacteria, yeast, protozoa, and animals, the organization of the enzymes 
responsible for these steps vary from the single enzymatic proteins of the bacteria to the 
multienzymatic protein of animals (Figure 1.4).  The evolution of the multifunctional 
characteristic of CAD appears to have involved gene duplication, gene translocation, and 
gene fusion events.  The E. coli carA gene encodes the small subunit of the E. coli 
CPSase (described previously).  Like the GLNase region of CAD, the small CPSase 
subunit (GLNase) catalyzes the formation of ammonia from glutamine.  The small 
subunit forms interactions with the large CPSase subunit (encoded by the carB gene) 
allowing for the efficient transfer of glutamine   
 The large E. coli CPSase subunit is a 120 kDa enzyme that consists of highly 
homologous amino- and carboxy-terminal halves, which appear to have arisen from the 
duplication of a smaller ancestral gene (Nyunoya and Lusty, 1983).  The two halves of 
CPSase II gene CPS.A and CPS.B (Figure 1.3) are highly homologous to the 
corresponding sections of the E. coli enzyme.  Interestingly, although it appears that the 
CPS.A and CPS.B domains of CAD perform separate distinct functions as described 
above, when they were cloned and expressed separately, they were both observed to 
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catalyze the complete formation of carbamoyl phosphate (Guy and Evans, 1996).  These 
data seem to further support the hypothesis that the CPS.A and CPS.B arose from the 
duplication and fusion of a smaller ancestral gene. 
 The carA and carB genes are separated by cistrons on a single operon in E. coli 
and other bacteria.  Davidson and colleagues have hypothesized that a mutation of a stop 
codon between the carA and carB genes caused the formation of a CPSase II gene, which 
encoded a protein carrying the enzymatic activities of both the small and large subunits 
(reviewed in Davidson et al., 1993). 
 It is thought that after the eukaryotes split into animal and plant kingdoms that the 
ATCase and DHOase genes fused to the CPS gene creating the CAD gene.  However, the 
duplication of the DHOase gene probably occurred prior to this fusion since yeast have a 
gene (URA4) that encodes the DHOase protein separated from the gene that encodes a 
protein with the CPSase and ATCase activities (URA2).  Interestingly, the URA2 gene 
contains a region that is homologous to the sequences from DHOase from mammals and 
E. coli, but it is not catalytically active (reviewed in Davidson et al., 1993).   
 The selective advantages of the formation of multienzymatic protein CAD have 
been investigated. One hypothesis is that the close proximity of active sites on CAD 
allowed substrates of each enzyme to be channeled from one active site to the other 
without being degraded by catabolic enzymes.  Jones and colleagues suggested that this 
“substrate channeling” occurred in CAD when they observed low cellular concentrations 
of carbamoyl phosphate and carbamoyl aspartate (Christopherson and Jones, 1980).   
Further evidence for the existence of substrate channeling in CAD was demonstrated 
when it was observed that endogenously-added carbamoyl phosphate was not 
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significantly used in the synthesis of carbamoyl aspartate, suggesting that the active sites 
were inaccessible to carbamoyl phosphate in the bulk solvent (Guy and Evans, 1994a).  
An additional selective advantage in having three enzyme activities in one protein is that 
the activities are coordinately regulated preventing the energetically wasteful process of 
creating substrates for subsequent enzymes in a pathway before those enzymes have been 
synthesized (Christopherson and Jones, 1980; Christopherson et al., 1981). 
1.6    CAD and embryological development 
 Although currently little is known about the regulation of CAD during 
mammalian embryogenesis, studies with other organisms have demonstrated the 
importance of CAD activity during development.  Studies using Drosophila showed that 
the unfertilized egg and early embryos had the highest activity of CAD, while enzymatic 
activity decreased rapidly during the first 24 hours after egg laying, reaching a minimum 
at the start of the first-instar larval stage.  Between the first- and second-instar larval 
stages, CAD activity increased significantly.  However, CAD activity began to decrease 
again until the end of the third instar larval stage.  CAD activity then rose slightly but 
steadily through the pupa stages and into the adult stage (Mehl and Jarry, 1978).  The 
molecular mechanisms by which CAD activity was regulated during Drosophila 
development have not been determined; these changes might result from transcriptional 
regulation and/or posttranslational modification of CAD, such as phosphorylation and/or 
caspase-mediated degradation (reviewed in Huang and Graves, 2003).    
 Mutations in Drosophila (r) that inhibited enzymatic activity have been identified 
(Jarry and Falk, 1974; Norby, 1973; Rawls and Fristrom, 1975).  The rudimentary 
mutation caused lethality when the flies were grown on pyrimidine-deficient media; 
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however, when grown on media containing normal levels of pyrimidines, the flies 
exhibited small and abnormally shaped wings.  Additionally, females homozygous for the 
rudimentary mutation were sterile when grown on normal pyrimidine containing media 
(Norby, 1970). These results demonstrated that CAD had tissue specific roles during 
Drosophila development.   
 As in Drosophila, CAD function is critical for the normal embryological 
development of zebrafish.  It was found that CAD transcripts were maternally supplied to 
the egg since CAD mRNA was present before the start of zygotic transcription.  During 
development, CAD mRNA levels appeared to be highest in the cells that were rapidly 
proliferating or initiating differentiation.  When CAD mRNA levels were reduced using 
antisense oligonucleotides during zebrafish embryogenesis, tissue specific abnormalities 
were observed.  The most dramatic phenotypes were the reduced eye size and inhibition 
of the differentiation of jaw and fin cartilage.  Interestingly, the data suggested that the 
normal retinal development required CAD activity for the formation of nucleotides for 
RNA and DNA synthesis; whereas, UDP-dependent glycosylation was necessary for the 
normal differentiation of cartilage (Willer et al., 2005).   
 The role of CAD in the development of C. elegans was investigated when 
Okkema and colleagues discovered that a spontaneous mutation in the DHOase domain 
of C. elegans CAD (pyr-1 (cu8)) caused a loss of DHOase activity.  The pyr-1 (cu8) 
mutation caused morphological defects and maternal effect lethality, as was seen in 
rudimentary mutations observed in Drosophila (described above).  While this mutation 
was lethal to 95% of late stage embryos, the 5 % that survived had defects in pharyngeal 
morphogenesis and were shorter when compared to wild-type worms.  As was found with 
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the Drosophila rudimentary mutations, the embryogenic lethality could be prevented by 
supplying exogenous pyrimidines to the growth media (Franks et al., 2006) 
1.7   CAD gene transcription 
 CAD activity is well correlated with cellular growth, as rapidly growing tissues, 
such as fetal liver, spleen, testis and clonally expanding lymphocytes, have much higher 
CPSase II activity than slower growing tissues including lung, uterus, heart, brain and 
muscle.  Additionally, various types of tumor cells display elevated CPSase II activity 
(Aoki et al., 1982a; Aoki and Weber, 1981; Ito and Uchino, 1971; Yip and Knox, 1970).  
One mechanism by which CPSase II activity is increased is through elevated transcription 
and expression of CAD.  CAD mRNA levels are low in quiescent cells such as 
unstimulated lymphocytes (Wauson, unpublished data), serum starved cells and contact 
growth inhibited cells (Liao et al., 1986; Rao and Davidson, 1988). Following serum 
stimulation of quiescent cells, CAD mRNA levels increased approximately 10-fold at the 
G1/S boundary (Rao and Church, 1988).  Werner and colleagues observed that CAD 
mRNA increased within 5 hours of both KGF or EGF treatment of quiescent 
keratinocytes (Gassmann et al., 1999).  Moreover, Snow and colleagues observed that 
CAD transcription was induced as B cells moved into and through the G1 cell cycle phase 
after stimulation with PMA and ionomycin, LPS, or anti-IgM plus Il-4.  Another earlier 
study showed that CAD specific activity was induced 5-fold over 70 hours in PHA-
stimulated primary human lymphocytes.  Since this increase was dependent on the 
synthesis of both RNA and protein, it was concluded that PHA induced CAD 
transcription (Ito and Uchino, 1971). 
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The mechanisms behind the growth-induced induction of CAD gene transcription 
have been investigated extensively.  The CAD promoter contains transcription factor 
consensus binding sequences for E2f, Sp1, Myc, Max, and USF transcription factors 
(Boyd and Farnham, 1997; Miltenberger et al., 1995). While it has not been determined 
which transcription factor maintains the basal gene transcription, the large growth-
induced increase in CAD transcription was mediated by the E-box at +65 in the CAD 
promoter (Miltenberger et al., 1995).  Additionally, it was determined that although the 
transcription factors USF, Myc, and Max bind to the CAD E-box in vivo, it was the Myc-
Max heterodimer that was responsible for growth-regulated CAD expression (Boyd and 
Farnham, 1997).  Studies in c-myc null cells confirmed that CAD was a c-Myc target 
gene (Bush et al., 1998).   Further studies have shown that the CAD gene is induced in 
estrogen receptor positive breast cancer cells by estrogen receptor/Sp1 complexes in 
response to17-estradiol.  Moreover, mutational analysis of the CAD promoter showed 
that the E-box is not necessary for 17-estradiol induced or basal CAD transcription in 
the breast cancer cell line (Khan et al., 2003).  Thus, it appears that in some cell types, 
Myc is necessary for mitogen-induced CAD gene transcription, while in other cell types, 
transcription factors such as Sp1 are required. 
 Cellular cues, such as serum removal, induction of differentiation, and hypoxia, 
can induce a decrease in cellular levels of CAD mRNA.  Two studies demonstrated that 
12 hours incubation of cells in low serum growth conditions, CAD RNA levels remained 
unchanged, but by 24 hours, the cells displayed a ten-fold decrease in CAD mRNA when 
compared to cells growing in normal levels of serum (Liao et al., 1986; Rao and 
Davidson, 1988).  Furthermore, CAD mRNA levels in HL-60 (human promyelocyte 
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leukemic cell line) cells drop significantly within 12 hours of the application of a 
differentiation stimulus (Rao et al., 1987).  Additionally, data from our laboratory 
suggests that CAD levels decrease after the differentiation of myoblasts into myocytes 
(Lee Graves unpublished data).  While the mechanism for the decrease of CAD gene 
transcription is not known, it may be due decreased c-Myc expression that occurs during 
serum starvation and myoblast and HL-60 differentiation (Reitsma et al., 1983; Wisdom 
and Lee, 1990; Yeilding et al., 1998).  However, Mac and Farnham observed that CAD 
expression was not deregulated in Burkitt’s lymphoma cell lines that overexpressed c-
Myc, suggesting that mechanisms other than c-Myc expression also regulate CAD gene 
expression (Mac and Farnham, 2000).  Indeed, Sif and colleagues observed that the 
repression of c-Myc-induced CAD transcription was caused by chromatin remodeling 
and histone deacetylation (Pal et al., 2003).  Another mechanism for the downregulation 
of CAD transcription appears to be the direct interaction of hypoxia inducible factor-1 
alpha (HIF-1alpha) with the CAD promoter (Chen et al., 2005). 
1.8    Chemical Inhibitors of CAD 
In 1971, Collins and Stark reported on the synthesis of the rationally designed 
ATCase inhibitor N-(phosphonacetyl)-L-aspartate (PALA).  The structure of PALA 
resembles the two natural substrates of ATCase, carbamoyl phosphate and aspartate, and 
inhibits the carbamoyl phosphate binding and aspartate binding to ATCase in a 
competitive and noncompetitive manner, respectively (reviewed in (Grem et al., 1988)).  
100 µM PALA was observed to prevent cellular division and kill the majority of the cells 
in a culture of SV40-transformed hamster kidney.  This cytotoxicity was attributed to the 
inhibition of de novo pyrimidine synthesis since 100 µM of exogenously added uridine 
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completely inhibited the cell death and cell cycle arrest. During these studies it was 
observed that a small number of the hamster cells were resistant to 100 µM PALA 
(Swyryd et al., 1974).  In subsequent studies, PALA-resistant cells were subjected to 
incremental increases in the PALA concentrations up to 25 mM.  It was concluded that 
the resistance was due to the increase in CAD mRNA and protein and the subsequent 
100-fold increase in ATCase activity (Kempe et al., 1976; Padgett et al., 1979).  Stark 
and colleagues determined that the increase in CAD levels in PALA resistant cells was 
due to the amplification of the CAD gene (Wahl et al., 1979).    Phase I and II clinical 
trials were performed with PALA; however, dose-limiting gut toxicities and tumor 
resistance due to CAD gene amplification prevented the use of PALA as a treatment 
option (reviewed in Grem et al., 1988). 
 Acivicin was another compound observed to inhibit CPSase II activity.  Acivicin 
is a naturally occurring L-glutamine antagonist antibiotic discovered to be released from 
Streptomyces sviceus (Jayaram et al., 1975).  Cooney and colleagues determined that the 
combined treatment of mice bearing tumors consisting of a PALA resistant Lewis Lung 
cell line with acivicin and PALA effectively inhibited CPSase II and ATCase activity 
respectively, causing tumor growth arrest and increased life spans (Kensler et al., 1981).  
However, since acivicin is a glutamine antagonist, it can inhibit numerous glutamine 
transferase enzymes, making the determination of the mechanisms by which it inhibits 
tumor growth difficult.  In fact, Christopherson and colleagues observed that acivicin was 
a potent inhibitor of CTP-synthetase and GMP-synthetase, but not CPSase II, in intact 
leukemia cells (Lyons et al., 1990). 
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Current research is underway to investigate ways of inhibiting CPS II activity to 
treat diseases caused by the protozoa such P. falciparum (the malarial parasite).  Stewart 
and colleagues observed that there was a significant decrease in viability of P. falciparum 
when in vitro cultures were treated with hammerhead ribozymes that targeted regions of 
the CPS II gene.  Another protozoan that is sensitive to the inhibition of CPS II is the 
toxoplasmic encephalitis causing parasite T. gondii.  Fox and Bzik created T. gondii 
strains that were CPS II null, and thus lacked detectable CPSase II activity.  When mice 
were injected with the normal CPS II containing strains of T. gondii, they succumbed to 
the infection within 9 days.  However, the mice that were injected with the CPS II null 
strains of T. gondii survived for greater than 6 months with no apparent parasite infection 
(Fox et al., 2002). 
1.9    Post-translational regulation of CAD  
1.9.1    CAD Phosphorylation 
 Early studies by Tatibana and colleagues showed that CAD was phosphorylated 
in vitro by the purified catalytic subunit of cyclic adenosine monophosphate (cAMP)-
dependent protein kinase (PKA) (Otsuki et al., 1981).   PKA was first discovered to be an 
effector of cAMP by Krebs and colleagues (Walsh et al., 1968).  cAMP is synthesized 
from ATP by the adenylyl cyclase (AC) enzyme in response to numerous cellular 
signaling molecules, such as hormones, neurotransmitters, and growth factors.  Ligand 
bound G-protein coupled receptors release Gs or Gi subunits that activate or inhibit the 
membrane bound adenylyl cyclase (AC), respectively.  Ten isoforms of AC have been 
identified in mammals with noted differences in tissue distribution (reviewed in Tasken 
and Aandahl, 2004).   
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The cAMP-modulated increase in PKA has been extensively studied.  PKA is a 
holoenzyme consisting of two catalytic subunits (C) and a dimer of two regulatory 
subunits (RI and RII).  cAMP binds each of the RI and RII subunits at sites A and B in a 
cooperative manner.  The binding of cAMP molecules induces a conformational change 
that allows the catalytic subunits to be released into active monomers (reviewed in (Kim 
et al., 2006).  The active PKA monomers then can phosphorylate serine and threonine 
residues on numerous substrate proteins (reviewed in (Tasken and Aandahl, 2004).  PKA 
is known to phosphorylate serine and threonine residues on over 100 different proteins 
with the optimal amino acid consensus motif being R-R-X-S	/T	 (* denotes 
phosphorylated residue) (reviewed in Shabb, 2001).   
 The first study to show that CAD was phosphorylated by PKA demonstrated that 
this kinase induced an incorporation of 2.2 mol 32Pi/mole of CAD.  Additionally, they 
observed that PKA-mediated CAD phosphorylation caused a slight increase in CPSase II 
activity by decreasing the apparent Km value for MgATP (Otsuki et al., 1981).  Hardie 
and colleagues subsequently confirmed that CAD was phosphorylated by PKA in vitro 
and further showed that the sites of in vitro phosphorylation were Ser1406 and Ser1859 
(Figure 1.6).  Additionally, while they confirmed that there was a slight increase in 
CPSase II activity after PKA phosphorylation, they observed that the ability of UTP to 
inhibit CPSase II activity was significantly reduced (Carrey et al., 1985).  A further study 
showed that while the S. cerevisiae enzyme URA2 (described above) was phosphorylated 
in vitro by PKA, its enzymatic activity or allosteric regulation was not affected (Denis-
Duphil et al., 1990).   
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To further investigate the effect of PKA phosphorylation on allosteric regulation, 
Evans and colleagues constructed an E. coli/hamster CPSase chimeric protein that had 
the E. coli CPSase A1 and A2 subdomains fused to the hamster CAD CPSase B3 
subdomain (the subdomain that binds the allosteric regulators UTP and PRPP as 
described above) (Figure 1.4).  They reported that PKA phosphorylation of the chimera 
caused it to become insensitive to UTP inhibition as previously demonstrated by Carrey 
and colleagues (Carrey et al., 1985).  No change in the response to saturating levels of 
PRPP was observed between the phosphorylated or unphosphorylated chimera; however, 
it was reported that phosphorylation of chimera by PKA did cause a significant decrease 
in the affinity for PRPP (Sahay et al., 1998). 
 As described above, Carrey and colleagues discovered that Ser1859 was 
phosphorylated in the amino acid linker region between the DHOase and ATCase CAD 
domains (Figure 1.6).  To investigate the function of this linker region and the 
phosphorylation of Ser1859, Guy and Evans examined the effect of the deletion of this 
amino acid segment on CAD activity, allosteric regulation, and substrate channeling.  
They demonstrated that both the deletion of the linker region, or the PKA-induced 
phosphorylation of wild-type CAD, caused a significant decrease in channeling of 
carbamoyl phosphate between the CPSase and ATCase when compared to 
unphosphorylated wild-type CAD.  Additionally, they determined that the PKA induced-
phosphorylation of the deletion mutant (which lacks Ser1859) induced a decrease in UTP 
inhibition and PRPP activation of CAD.  Therefore, the authors concluded that the effect 
of the phosphorylation of Ser1406 was decreased UTP inhibition and reduced PRPP 
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stimulation and that the phosphorylation of Ser1859 caused a decrease in substrate 
channeling (Guy and Evans, 1994c). 
 Davidson and colleagues performed the first studies designed to investigate the 
PKA-induced CAD phosphorylation in vivo.  CAD was observed to be phosphorylated in 
cells after the stimulation of PKA with 8-Br-cAMP.  Furthermore, the phosphorylation 
was reduced in cells that were pretreated with the PKA inhibitor H89.  Since PKA 
phosphorylated Ser1406 in vitro, it was hypothesized that this was the CAD site 
phosphorylated in intact cells.  However, these authors reported no decrease in the 
phosphorylation of CAD that had Ser1406 mutated to Ala1406  (S1406A) (a residue not able 
to be phosphorylated) when compared to wild-type CAD.  While these data suggested 
that Ser1406 was not the in vivo PKA-induced CAD phosphorylation site, the authors 
noted that the basal level of CAD phosphorylation in the absence of PKA stimulation 
may have prevented them from observing the loss of CAD phosphorylation in the 
S1406A mutant (Banerjei and Davidson, 1997). 
 Interestingly, when the Ser1406 CAD residue was mutated to the phospho-mimetic 
Glu1406 (S1406E) residue, there was an increase in CAD activity and a decrease in the 
UTP-induced allosteric inhibition.  Furthermore, there was no observed effect on the 
PRPP-induced stimulation of CPSase II (Banerjei and Davidson, 1997). Using a Glu as a 
phospho-mimetic suggested that the function of the phosphorylation of Ser1406 was to 
increase CAD activity and decrease UTP inhibition.  However, no catalytic or allosteric 
affect was observed in a subsequent study in which the Drosophila CAD rudimentary (r)
serine residue corresponding to Ser1406 was mutated to the Glu (Simmons et al., 1999).  
Moreover, the CAD activity or allosteric regulation was not measured from forskolin-
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treated cells that displayed PKA-induced CAD phosphorylation (Banerjei and Davidson, 
1997).  Therefore, the role of PKA-induced CAD phosphorylation in cells remained 
unclear. 
 During studies designed to determine substrates of the extracellular signal-
regulated kinase1/2  (ERK1/2), Graves and colleagues demonstrated that ERK1/2 
phosphorylated CAD in vitro. ERK1/2 is a member of the mitogen-activated protein 
kinases (MAPKs) and is activated in response to numerous physiological stimuli.  Well-
characterized activators of ERK are the growth factors, platelet derived growth factor 
(PDGF) and epidermal growth factor (EGF).  By binding cell membrane receptors, EGF 
and PDGF activate a kinase cascade causing MAP kinase kinase kinases (MKKKs) to 
phosphorylate and activate MAP kinase kinases (MKKs).  The MKKs, MEK1 and MEK2 
then activate ERK1/2 by phosphorylating tyrosine and threonine residues in the 
activation domain.  ERK1/2 phosphorylates numerous substrates, which are involved in 
diverse cellular processes such as proliferation, differentiation, and apoptosis (reviewed 
(Cuevas et al., 2007; Raman et al., 2007). 
 ERK1/2 were observed to phosphorylate CAD in vitro on Thr456. Furthermore, 
the stimulation of ERK activity in the liver cell line GN4 by platelet derived growth 
factor (PDGF) induced CAD phosphorylation.  It appeared that the phosphorylation of 
CAD caused a decrease in UTP inhibition and an increase in PRPP stimulation.  
However, the authors noted that it remained to be determined whether Thr456 was a major 
in vitro or in vivo ERK phosphorylation site (Graves et al., 2000). 
 To investigate the role of PKA- and ERK- mediated phosphorylation of CAD in 
vivo, Guy and colleagues performed studies using BHK 165-23 cells, a cell line that was 
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induced to overexpress CAD over 100-fold by selecting cells that were resistant to 
treatments with PALA.  To determine if CAD phosphorylation was affected during 
cellular growth, CAD was immunoprecipitated from cells that were harvested every 24 
hours for six days after plating.  SDS-PAGE and immunoblotting using general phospho-
threonine and phospho-serine antibodies was performed.  They reported that CAD had 
increased threonine phosphorylation during exponential cellular growth when ERK was 
active and more serine phosphorylation as the growth of the cells slowed and there was 
higher PKA activity.  Furthermore, the authors demonstrated that during times of high 
ERK activity and low PKA activity PRPP could stimulate CAD activity by 22-fold; 
however, when there was low ERK activity and high PKA activity, PRPP could only 
stimulate CAD by 6-fold.  There was an observed increase in de novo pyrimidine 
synthesis during the exponential cellular growth when ERK levels were high.  Therefore, 
the authors concluded that the physiological function of ERK-mediated CAD 
phosphorylation was to cause an increase in CAD activity thereby increasing pyrimidine 
pools needed for cellular growth.  Additionally, they hypothesized that the role of PKA 
phosphorylation of CAD was to inhibit enzyme activity by decreasing PRPP stimulation 
during slowed cellular growth when high levels of pyrimidines were not needed (Sigoillot 
et al., 2002b). 
 To further investigate the role of ERK phosphorylation of CAD, Guy and 
colleagues used an antibody designed to recognize CAD pThr456 to determine if higher 
levels of pThr456 correlated with the increased CAD activity in the MCF7 breast cancer 
cell line.  In this study it was reported that MCF7 cells had higher levels of active ERK 
and higher levels of phosphorylated CAD residue Thr456, and U0126, a MEK-1 inhibitor, 
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appeared to decrease the pThr456 levels in MCF7 cells (Sigoillot et al., 2004).  In more 
recent studies the pThr456 specific antibody was used to demonstrate that levels of CAD 
phosphorylated on Thr456 were enriched in the insoluble nuclear fraction of numerous cell 
types including MCF7 and HEK-293.  It was proposed that CAD was most active in the 
nucleus where it was phosphorylated on Thr456 by ERK.  Furthermore, it was 
hypothesized that nuclear localization of active CAD allowed for more efficient 
pyrimidine biosynthesis since the perinuclear region is enriched with mitochondria, and 
that dihydroorotate (the product of CAD) could be channeled directly to the 
mitochondrial DHODH without having to equilibrate into the cytoplasm (Sigoillot et al., 
2005).  
 In addition to being phosphorylated by ERK and PKA, Evans and colleagues 
proposed that CAD was autophosphorylated.  This proposal was based on the 
demonstration that the incubation of CAD, purified from BHK 165-23 cells, with [-
32P]ATP caused a 0.97 mol of phosphate incorporated per mol of CAD.  Additionally, the 
authors reported that unpublished mass spectrometry data suggested that Thr1037 was the 
autophosphorylation site in CAD.  Moreover, since CAD that was pre-incubated with 
ATP and kinase buffer had greater CPSase II activity and responded differently to 
allosteric effectors when compared to CAD that was not pre-incubated with ATP and 
kinase buffer, the authors concluded that these enzymatic changes were the result of the 
autophosphorylation of Thr1037 (Sigoillot et al., 2002a).  Whether or not Thr1037 is an in 
vivo CAD phosphorylation site remains to be determined.   
 By performing a mass spectrometric global analysis of phosphorylation sites in 
proteins from HELA cells stimulated with EGF, Mann and colleagues discovered 6,600 
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putative phosphorylation sites on 2,244 proteins.  According to the published database 
from this work (PHOSIDA.COM), CAD was phosphorylated on residues Ser1823, Ser1859,
Ser1900, Ser1920, Ser1928, and Thr1933 (Figure 1.6).  Furthermore, an EGF-induced increase 
in the phosphorylation of Ser1900, Ser1920, Ser1928, and Thr1933 was noted (Olsen et al., 
2006).  In a tyrosine specific global phosphorylation analysis performed by Comb and 
colleagues, it was reported that CAD isolated from pervanadate and calyculin treated 
Jurkat or K562 cells was phosphorylated on Tyr735, Tyr1884, and Tyr1890 (Identified with 
Phosphosite at www.phosphosite.org) (Rush et al., 2005).   In additional studies, Evans 
and colleagues reported that the PKC phosphorylation of CAD at Ser1873 and the PKA 
phosphorylation of CAD at Ser1406 stimulate or inhibit ERK phosphorylation at Thr456 
respectively (Kotsis et al., 2007; Sigoillot et al., 2007). 
1.9.2    CAD Proteolysis 
 The apoptotic proteolytic enzyme caspase-3 was observed to cleave CAD during 
apoptosis.  The cleavage sites were determined to be at Asp1143 and Asp1371 in the B2 and 
B3 subdomains of CPSase II respectively (Figure 1.4).  The withdrawal of interleukin-3 
from a myeloid precursor cell line or the addition of staurosporine caused caspase-3-
mediated degradation of CAD that preceded the appearance of annexin-5 and DNA 
fragmentation, both late occurring events in cellular apoptosis.  A decrease in activity and 
allosteric activation of CAD, as well as a decrease in intracellular pyrimidine pools, 
paralleled the cleavage of CAD (Huang et al., 2002).  Tang and colleagues demonstrated 
in a recent study that physiological levels of nucleoside triphosphates (NTPs) bound to 
lysine residues on cytochrome C thereby preventing their interaction with Apaf-1, a key 
step in the subsequent activation of caspase-9 and the eventual cell death (Chandra et al., 
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2006).  Therefore, an interesting hypothesis is that the degradation of CAD and the 
consequent lowering of intracellular pyrimidines is necessary for cells to undergo 
efficient apoptosis.   
1.10    Protein-Protein Interactions 
 A study performed by Angeletti and Engler demonstrated that CAD was present 
in adenovirus replicative complexes on the nuclear matrix of cells infected with 
adenovirus.  More specifically, CAD formed a protein-protein interaction with the 
precursor of the terminal protein (pTP), the protein that initiates the stimulation of viral 
DNA chain extension.  Although BrdU staining demonstrated that the CAD-pTP complex 
was present at sites of active replication, the function of this complex was not 
determined.  Furthermore, large-scale protein-protein interaction screens have identified 
14-3-3 zeta (Meek et al., 2004) and the postreplicative mismatch repair enzyme PMS2 
(Cannavo et al., 2007) as CAD interacting proteins.  A study performed by Carrey and 
colleagues suggested that CAD was associated with the actin cytoskeleton in sperm 
(Carrey et al., 2002).  An additional protein-protein interaction between CAD and the 
human checkpoint protein hRad9 was found by our laboratory and is the subject of 
chapter III of this dissertation. 
1.11    Intraceullar location of CAD 
While the majority of CAD protein is reported to be cytoplasmic, CAD was 
observed in the nucleus in numerous studies (Angeletti and Engler, 1998; Carrey et al., 
2002; Sigoillot et al., 2003).  The function of nuclear CAD is currently unknown.  As 
described above, Evans and colleagues have reported that nuclear CAD is more efficient 
than cytoplasmic CAD in providing dihydroorotate to the mitochondrial DHODH 
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enzyme.  Therefore, they propose that the function of nuclear CAD is to increase the 
supply of cellular pyrimidine nucleotides.  The signal that induces the trafficking of CAD 
to the nucleus in mammalian cells is not known.  However, studies performed by Nagy 
and colleagues suggest that the yeast CAD homolog (Ura2) contains a bipartite nuclear 
localization sequence that directs it to the nucleus.  Furthermore, studies in our laboratory 
demonstrated that CAD became almost entirely nuclear when hRad9 was cotransfected 
with CAD in HELA and HEK-293 cells  (Brown and Graves, unpublished data).  
1.12    Rad9  
 DNA damage can be caused by the exposure of cells to ionizing radiation, UV 
radiation, and numerous types of chemicals during the course of cellular growth.  Since 
DNA damage can cause genomic instability leading to cellular death and pathological 
conditions such as cancer, the recognition and repair of this damage is critically 
important.  Cell cycle checkpoints have evolved to cause the inhibition of the progression 
of the cell cycle so that damaged DNA can be repaired.  Clearly defined checkpoints have 
been identified as the G1/S, intra-S, and G2/M checkpoints (reviewed in Sancar et al., 
2004)).  The recognition of DNA damage must first occur before the subsequent events 
leading to the eventual repair of DNA or the induction of apoptosis can occur.  This 
recognition step is performed by the DNA damage sensors, which include the kinases 
ATM and ATR, the Rad17-RFC complex, and the 9-1-1 complex.  The 9-1-1 complex is 
a homotrimer consisting of the hRad9, hRad1, and hHus1 proteins (reviewed in Sancar et 
al., 2004).  The N-terminus of hRad9 and the C-terminus of the PCNA-like region of 
hRad9 are the regions on hRad9 responsible for the interaction with hRad1 and hHus1 
respectively (Burtelow et al., 2001).  This complex forms a ring-like structure that is 
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loaded onto damaged DNA by the hRad17-RFC protein complex (Bermudez et al., 2003; 
Griffith et al., 2002; Lindsey-Boltz et al., 2001).  The 9-1-1 complex encircles damaged 
DNA and recruits other checkpoint proteins called mediators to the sites of damage.  
These mediators then activate the signal transducers, such as the checkpoint kinase Chk1, 
which subsequently inhibits cell cycle progression by targeting Cdc25 for ubiquitin-
mediated degradation (reviewed in Sancar et al., 2004).  In addition to the DNA damage 
sensor role of 9-1-1, this complex appears to also participate in DNA repair by directly 
binding to and activating DNA ligase I (Wang et al., 2006). 
 hRad9 can bind other cellular proteins outside the 9-1-1 complex.  A BH3 domain 
in the N-Terminal portion of Rad9 allows Rad9 to bind to the prosurvival proteins BCL-2 
and Bcl-xL (Komatsu et al., 2000).  The susceptibility to DNA damage-induced apoptosis 
was measured in cells transfected with either wild-type hRad9 or a BH3 deletion mutant 
of hRad9 that could not interact with BCL-2 or Bcl-xL.  The results suggested the function 
of Rad9 BCL-2/Bcl-xL interaction was the promotion of apoptosis (Komatsu et al., 2000).  
Subsequent studies demonstrated that DNA damage caused the c-Abl tyrosine kinase to 
phosphorylate hRad9 on Tyr28 thereby inducing the hRad9/ Bcl-xL interaction (Yoshida et 
al., 2002).  In addition, Kufe and colleagues provided evidence that suggested that the 
hRad9 interaction with BCL-2/Bcl-xL was also regulated by the direct phosphorylation of 
hRad9 by PKC delta (Yoshida et al., 2003). 
 The cellular localization of hRad9 has been investigated.  Transiently transfected 
hRad9 in HeLa cells was expressed throughout the cells with highest expression being in 
the nucleus (Komatsu et al., 2000).  Rad9 was primarily localized in the nucleus of the 
leukemia cell line K526 and in HEK 293 cells and hRad9 formed discrete nuclear foci 
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upon DNA damage (Burtelow et al., 2000).   Subsequent studies by Davey and 
colleagues demonstrated that hRad9 colocalized with other DNA damage sensing 
proteins at double stranded DNA breaks within 2 minutes of damage induction (Greer et 
al., 2003).  A nuclear localization sequence (NLS) located towards the C-terminus of the 
C-terminal domain of hRad9 was determined to be necessary for the DNA damage-
induced cell cycle arrest at G2/M phase.  Furthermore, it appeared that the NLS of hRad9 
was necessary for the nuclear localization of other 9-1-1 components (Hirai and Wang, 
2002).  Therefore, it appears that the NLS of hRad9 is critical for the checkpoint function 
of hRad9.  Since hRad9 bound to Bcl-2 and Bcl-xL outside the nucleus, the mechanism 
that allowed hRad9 to remain outside the nucleus was unclear.  However, studies by 
Wang and colleagues suggested that during apoptotic signals, caspase-3 cleavage of 
hRad9 caused the cytoplasmic accumulation of hRad9 (Lee et al., 2003). 
 While hRad9 is required for the normal response to DNA chemically and 
radiation induced DNA damage, the deletion of the mouse version of this gene, Mrad9, 
demonstrated that Rad9 was also necessary for normal embryogenesis.  The Mrad9-/- 
mouse embryos died between E9.5 and E12.5. Additionally, fibroblasts taken from 
Mrad9-/- embryos were not viable (Hopkins et al., 2004).  Experiments performed with 
Mrad9-/- embryonic stem cells demonstrated that the primary role of Mrad9, at least in ES 
cells, was to protect cells against DNA damage induced apoptosis (Loegering et al., 
2004). 
 Rad9 has been reported to have roles in addition to the direct checkpoint and 
apoptotic functions described above.  hRad9 was determined to be a transcription factor 
able to directly activate the transcription of the cyclin-kinase inhibitor p21 (Yin et al., 
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2004).  Further studies suggested that the mechanism by which Rad9 activated p21 
transcription was by forming a complex with the p53 protein and binding to the p21 
promoter (Ishikawa et al., 2007).  Additionally, hRad9 bound to and downregulated the 
activity of the androgen receptor (Liu et al., 2004).  Data presented in chapter 3 of this 
dissertation suggests that an additional role of hRad9 is the regulation of nucleotide 
synthesis by binding to CAD and activating CPSase II activity (Lindsey-Boltz et al., 
2004). 
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Figure 1.1.  Cellular Pyrimidine Synthesis. Pyrimidines nucleotides can be synthesized 
de novo from basic cellular molecules, or by the salvage of preexisting nucleosides.  The 
multifunctional protein CAD catalyzes the first three reactions in de novo pyrimidine 
biosynthesis. Dihydroorotate, the product of CAD, is then used by the mitochondrial 
membrane protein dihydroorotate dehydrogenase (DHODHase) to form orotate.  Orotate 
then is used by the multienzymatic protein UMP-synthetase to form UMP.  The 
extracellular nucleosides uridine and cytidine can be imported into cells by the 
equilibrative nucleoside transporters (ENTs) and the concentrative nucleoside 
transporters (CNTs).  Once inside the cell, uridine and cytidine are phosphorylated to 
UMP and CMP by uridine/cytidine kinase (UCK).  UMP/CMP kinase then 
phosphorylates UMP and CMP creating UDP and CDP, respectively.  Nucleoside 
diphosphate kinase (NDPK) catalyzes the formation of UTP and CTP.  While CTP can be 
formed by NDPK, CTP-Synthetase also catalyzes the formation of CTP from UTP.  UTP 
is used in the formation of RNA and UDP-sugars, while CTP is incorporated into RNA 
and converted into phospholipids.  Additionally, CDP is converted to deoxycytidine 
diphosphate (dCDP) by ribonucleotide reductase (RNR).  dCDP then is used to make 
dCTP and is incorporated into DNA.  RNR also converts UDP to dUDP.  dUDP is 
transformed in a series of steps into dTTP, which is also used in the synthesis of DNA. 
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Figure 1.2.  Chemical reactions in de novo pyrimidine synthesis. The CPSase II 
portion of CAD catalyzes the formation of carbamoyl phosphate.  Carbamoyl aspartate 
transcarbamoylase then uses aspartate and ATP to form N-Carbamoyl-aspartate.  N-
Carbamoyl-aspartate catalyzes the condensation of N-Carbamoylaspartate to 
dihydroorotate.  Dihydroorotate dehydrogenase then oxidizes dihydroorotate to orotic 
acid.  The orotate phosphoribosyltransferase domain of UMP-synthetase uses PRPP and 
orotate to form Orotidine monophosphate (OMP).  OMP is decarboxylated into UMP by 
the orotidine-5-phosphate decarboxylase, which is the second enzymatic domain of 
UMP-synthetase.  This image is from (Lagoja, 2005) and reproduced with permission.  
Copyright Wiley-VCH Verlag GmbH & Co. KgaA. 
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Figure 1.3.  Domain structure of CAD. The numbers represent hamster amino acids 
(Kim et al., 1992).  The amino acid numbers   CAD is a modular protein consisting of 
three distinct domains:  Carbamoyl phosphate synthetase II (CPSase II), Dihydroorotase 
(DHOase), and Aspartate transcarbamoylase (ATCase).  The CPSase II is further divided 
into the subdomains glutaminase (GLNase), CPS.A, and CPS.B.  The GLNase is on the 
N-terminal end of CAD, and is linked to the CPS.A. subdomain by a 30 amino acid linker 
region (amino acids 366-395).  CPS.A and CPS.B are the highly homologous subdomains 
of CPSase II.  The B3 region of CPS.B is the site of binding for the allosteric effectors 
PRPP and UTP.  The DHOase and ATCase domains are connected via the 129 amino 
acid linker region (DA). 
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Figure 1.4.  Evolution of CAD.  The evolution of the multifunctional protein CAD is 
hypothesized to have occurred from gene duplications and gene fusions.  Bacteria have 
four separate gene products that encode the four proteins:  Glutaminase (GLNase), 
Carbamoylphosphate synthetase (CPSase), Aspartate Transcarbamoylase (ATCase), and 
Dihydroorotase (DHOase).  Protozoa have a multifunctional protein that contains the 
GLNase and CPSase enzymatic activities.  Yeast have evolved the multifunctional 
protein that contains the GLNase, CPSase and ATCase enzymatic activities.  Finally, 
animals express the CAD protein, which contains all four of the enzymatic activities.   
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Figure 1.5.  CAD Regulation. Since CAD catalyzes the rate-limiting step in de novo 
pyrimidine biosynthesis, it is regulated at multiple levels.  Growth stimulatory signals can 
increase CAD transcription by increasing the activities of the c-Myc, SP1, and estrogen 
receptor (ER) transcription factors.  Additionally, kinases induced by growth factors have 
been reported to phosphorylate and activate CAD.  The hypoxia inducible factor-1
(HIF-1) can decrease CAD transcription during cellular hypoxic conditions.  CAD 
activity is allosterically activated by phosphoribosyl pyrophosphate (PRPP) and 
allosterically inhibited by UTP.  During apoptosis, CAD is degraded by caspase 3-
induced proteolysis. 
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Figure 1.6. Proposed CAD phosphorylation sites and the conservation of these sites 
in various species.  (A) A sequence alignment showing the degree of conservation 
between phosphorylation sites reported in hamster or human CAD and CAD from other 
species.  The sequences that were used have the following NCBI Accession numbers:  
Hamster (P08955); Human (P27708); C. elegans (NP_495838); Zebra fish (CAI20956); 
D. melanogaster (NP_523377); S. cerevisiae (CAA89425).  (B) The proposed CAD 
phosphorylation sites are found within the CPS.A, CPS.B, and ATCase subdomains and 
within the solvent exposed linker region between the DHOase and ATCase domains. 
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REGULATION OF CAD BY PHOSPHORYLATION 
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2.1    Introduction 
Pyrimidine nucleotides are used by cells to make complex molecules such as 
RNA, DNA, phospholipids, glycosylated proteins and are used as ligands for numerous 
members of the G protein-coupled P2Y receptor family (reviewed in (Connolly and 
Duley, 1999).  A recent study suggested that an additional role for pyrimidine nucleotides 
was the inhibition of apoptosis by binding to cytochrome C and inhibiting the 
apoptosome formation (Chandra et al., 2006).   De novo pyrimidine biosynthesis is 
important for rapidly proliferating cells and the robust increase in intracellular pyrimidine 
nucleotides is required for the mitogen-induced clonal expansion of lymphocytes 
(Ruckemann et al., 1998).   
CAD, the 243-kDa protein that initiates de novo pyrimidine synthesis, contains 
three enzymatic domains:  carbamoyl phosphate synthetase II (CPSII), aspartate 
transcarbamoylase (ATCase), and dihydroorotase (DHOase).  The CPSII activity of CAD 
is the rate-limiting step and is allosterically activated by phosphoribosyl pyrophosphate 
(PRPP) and inhibited by the product of pyrimidine-nucleotide synthesis, uridine 5-
triphosphate (UTP).  CAD activity is increased in tumor cells (Aoki and Weber, 1981; 
Denton et al., 1982) and mitogen-stimulated lymphocytes (Ruckemann et al., 1998).  In 
addition to allosteric regulation, total CAD activity can be elevated by gene amplification 
and increases in transcription in response to growth stimulatory signals (Gassmann et al., 
1999; Rao and Church, 1988; Reardon et al., 1987).  Furthermore, the acute regulation of 
CAD activity via post-translational modifications, such as caspase cleavage and 
phosphorylation, have been described (reviewed in (Evans and Guy, 2004; Huang and 
Graves, 2003).
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CAD can be phosphorylated by protein kinase A (PKA) in vitro on the amino 
acids Ser1406 and Ser1859. The phosphorylation of CAD by PKA increased enzymatic 
activity due to increased affinity for ATP and a decreased UTP inhibition (Carrey et al., 
1985; Otsuki et al., 1981).  Further studies showed that CAD was phosphorylated in 
intact cells, on an undetermined amino acid residue, after the cells were treated with 8-
Br-cAMP, an activator of PKA.  Additionally, H89, a PKA inhibitor, prevented the 8-Br-
cAMP-induced phosphorylation of CAD.  The mutation of Ser1406 to Glu1406, to mimic 
phosphorylation, caused the apparent Km (ATP) to be reduced and the IC50 of UTP to be 
increased; however, the mutation of Ser1406 to an Ala1406 did not alter the biochemical 
properties of CAD.  Furthermore, Evans and colleagues proposed that the physiological 
role of PKA phosphorylation of CAD is to decrease overall enzyme activity since they 
showed that PKA-induced phosphorylation of an E. coli/human chimera of CAD in vitro 
diminished the PRPP-induced increase in CAD activity (Sahay et al., 1998). 
CAD was shown to be phosphorylated in vitro by MAP kinase on Thr456. The in 
vitro phosphorylation of CAD by ERK and the stimulation of cells with epidermal 
growth factor (EGF) or platelet derived growth factor (PDGF) appeared to modulate the 
allosteric regulation of CAD (Graves et al., 2000).  While Thr456 could be phosphorylated 
in vitro by ERK, it remained to be determined whether this was the only site 
phosphorylated by this kinase in vitro and whether this site was phosphorylated in vivo.
Guy and colleagues have reported an antibody that recognized phosphorylated Thr456.
Data using this antibody suggested that CAD isolated from a breast cancer cell line had 
higher levels of phosphorylated Thr456 than CAD from non-cancerous control cells 
(Sigoillot et al., 2004).  However, the specificity of this antibody was not reported.   
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In addition to PKA and ERK phosphorylating CAD, there is a report that CAD 
partially isolated from the cell line BHK-165-23, was autophosphorylated on Thr1037 
(Sigoillot et al., 2002a).  BHK 165-23 is a hamster kidney cell line that was induced to 
overexpress CAD over 100-fold by exposing the cells to the ATCase inhibitor, N-
phosphonacetyl-L-aspartate (Padgett et al., 1979). CAD reportedly “autophosphorylated” 
when incubated with ATP and a kinase buffer.  Additionally, it was reported that 
autophosphorylated CAD had a 2-fold increase in CPSase II activity, a decrease in the 
activation by PRPP and an increase in sensitivity to the allosteric inhibitor UTP (Sigoillot 
et al., 2002a).   
The physiological relevance of CAD phosphorylation is not well understood.  
Guy and colleagues reported that the phosphorylation of serine and threonine sites on 
CAD fluctuate with the cell cycle and that these phosphorylation events modulated the 
allosteric regulation of CAD.  Since Ser1406 and Thr456 were shown to be in vitro PKA 
and MAP kinase phosphorylation sites, respectively, this group used phospho-serine 
antibodies to measure the PKA-induced phosphorylation of Ser1406 and the MAP kinase-
induced phosphorylation of Thr456. Using this premise, Guy and colleagues proposed that 
increased CAD allosteric activation during the S-phase of hamster kidney cells was due 
to MAP kinase phosphorylation and that this was responsible for the 1.9 fold increase in 
the pyrimidine biosynthetic pathway observed during S phase.  Furthermore, they 
proposed that the PKA-induced phosphorylation of CAD accounted for the decrease in 
CAD activity that was observed in cells following S-phase. 
While it has been proposed that CAD is phosphorylated by ERK solely on Thr456,
and by PKA on Ser1406 and Ser1859 in cells, these sites have not been confirmed in CAD 
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from intact cells.  Furthermore, there are reports of additional phosphorylation sites in 
CAD (Olsen et al., 2006; Sigoillot et al., 2007).  Therefore, a major objective in this study 
was to perform a comprehensive identification of the in vivo CAD phosphorylation sites 
by using 2D-phosphopeptide mapping, site-directed mutagenesis, and a variety of mass 
spectrometric approaches.  Additionally, we tested the ability of ERK and PKA to 
phosphorylate CAD in HEK-293 cells.  While we determined that forskolin-induced PKA 
activity increased the phosphorylation of Ser1406 and Ser1859, surprisingly, we observed 
that CAD was not a substrate for ERK in HEK-293 cells.  To investigate the effect of 
CAD phosphorylation on enzymatic activity, we measured CPSase II activity from CAD 
isolated from forskolin treated HEK-293 cells, from phosphorylation-null mutants, and 
from CAD isolated from HEK-293 cells treated with a phosphatase.         
2.2    Materials and Methods 
2.2.1    Materials   
Antibodies that recognized the indicated antigens were as follows: pThr456 and 
pERK2 from Santa Cruz Biotechnology, mouse anti-Flag M2 from Sigma, and the 
secondary HRP antibodies from Santa Cruz Biotechnology.  The MEK-1 inhibitor U0126 
and the adenylyl cyclase activator forskolin were purchased from CalBiochem.  Both 
compounds were dissolved in DMSO and stored at –20 °C. The anti-Flag M2 resin was 
purchased from Sigma and the Ni-NTA resin was purchased from Qiagen.  The PRPP 
was purchased from Sigma, dissolved in H2O to a concentration of 75 mM and stored at –
70 °C.  The [32P]-orthophosphate and [14C]-sodium bicarbonate were purchased from MP 
Biomedicals.  The [32P]ATP was purchased from Perkin Elmer.  The GST-14-3-3
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expression vector was a gift from Dr. Helen Piwnica-Worms and is described in (Meek et 
al., 2004).     
2.2.2    Cell Growth and Transfection   
Human embryonic kidney (HEK-293) cells were grown in Dulbecco’s modified 
Eagle’s medium (Invitrogen) supplemented with 10% heat inactivated fetal bovine serum 
(FBS) and 100 U/ml of penicillin and streptomycin (Invitrogen) in an atmosphere of 5% 
CO2 at 37 °C.  Cells were plated at a density of approximately 2.5 * 106 cells per 100 mm 
tissue culture plate the day before the cells were transfected with 5.6 µg of the various 
constructs using Lipofectamine (Invitrogen) per manufacturer’s protocol.  Cells were 
grown in 10 % FBS (normal growth media) for either 24 hours after transfection or 
placed in 0.2 % FBS  (low serum growth media) for an additional 18-24 hours before 
subsequent treatments.   
2.2.3    Mutagenesis 
The wild type CAD used in this study was hamster CAD cDNA that was 
subcloned into PCDNA3.1 HIS (Invitrogen) described previously (Graves et al., 2000).  
An additional 3X-FLAG sequence was placed on the N-terminus.  We used a 
Quickchange XL II kit (Stratagene, La Jolla, CA) to make the CAD mutants T456A, 
T1037A, T1037E, S1038A, S1406A, S1823A, S1859A, S1900A, S1920A, S1928A, and 
T1933A per manufacturer’s instructions.  Each mutation was verified by DNA 
sequencing. 
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2.2.4    Metabolic labeling with [32P]-orthophosphate, cell treatments, and 
immunoprecipitation 
After HEK-293 cells were transfected and grown in either low serum or normal 
growth media as described above, the cells were rinsed once in 5 ml of phosphate free 
DMEM (sodium phosphate and sodium pyruvate free with sodium pyruvate (Invitrogen 
Inc.) added to a final concentration of 110 mg/ml of sodium pyruvate.  3 ml of phosphate 
free DMEM with either 10 %, or 0.2 % dialyzed FBS (Invitrogen Inc.) was added to the 
plates and the cells were allowed to incubate for 30 min. in the normal cell growth 
conditions described above.  Then to each plate 1-2 mCi of [32P]-orthophosphate (0.33 
mCi/ml, MP Biomedical) was added.  The cells were treated with 20 µM forskolin, or 
stimulated with 10 % fetal bovine serum 3-4 hours after the addition of the [32-P]-
orthophosphate.  15 min after the addition of forskolin or 10 min, 30 min, or 60 min after 
the addition of 10 % serum, the plates were placed on ice, the media was removed, and 
the cells were rinsed twice in 10 ml of ice-cold phosphate buffered solution (PBS).  125 
µl of ice-cold cell lysis buffer (20 mM Tris-HCl (pH 7.5), 137 mM NaCl2 10% glycerol, 
5 µg/ml leupeptin, 250 µM phenylmethylsulfonyl fluoride (PMSF) 100 nM microcystin, 
200 µM Na3VO4, and 2 mM ATP) was added to each plate and the cells were removed 
by scraping.  The cell lysates then were centrifuged at 18,000 x g for 15 minutes at 4 °C, 
Flag-CAD was immunoprecipitated by adding 6 µl of anti-Flag agarose resin (Sigma) 
(suspended in a 1:1 solution of agarose beads:lysis buffer) per 1 mg of protein to 
microfuge tubes and rolling the tubes end-over-end at 4 °C for 3-4 hours.  The anti-Flag 
agarose then was washed twice in 1 milliliter of ice-cold lysis buffer, and Flag-CAD was 
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removed by boiling the beads for 4 minutes in 2X SDS sample buffer (0.5 M Tris pH 6.8, 
4 % SDS, 20 % glycerol, 10 % -mercaptoethanol, 0.002 g/ml bromophenol blue).   
2.2.5    CAD activity assay 
CPSase II activity was measured essentially as described previously (Huang et al., 
2002). Briefly, all of the reaction components except the cold and [14C]- labeled sodium 
bicarbonate (the initiation solution) were added to 1.7 ml microfuge tubes on ice.  The 
reaction mixture contained 41 µl of Flag resin bound to the immunoprecipitated Flag-
CAD suspended in cell lysis buffer (described above).  174 µl of CAD Reaction solution 
(87 mM Tris-HCl (pH 8.0), 87 mM KCl, 6.5% dimethyl sulfoxide, 2.2% glycerol, 0.87 
mM dithiothreitol, 3.1 mM glutamine, 17.4 mM aspartate, 7 mM [14C]NaHCO3 (50 
mCi/mmol), 2 mM excess of MgCl2 over the nucleotide (ATP) and PRPP concentrations,
and ATP concentrations (adjusted to ATP contained within the cell lysis buffer) was 
added to each reaction.  These samples then were placed in a 37°C water bath for 5 
minutes before the initiation mix was added to start the reaction. The 250 µl reaction was 
allowed to proceed for 30 minutes at 37°C before it was quenched by the addition of 125 
µl of 80 % trichloroacetic acid. The unincorporated 14C then was removed by gently 
heating the samples at 85° C for 2-3 hours. 5 ml of Scintisafe  Econo 2 was added to 
each sample and the incorporation of 14C into the acid stable carbamoyl aspartate was 
measured by liquid scintillation counting.  The CAD protein concentrations used in the 
assay were determined by comparison to bovine serum albumin standards on a coomassie 
stained gel after SDS-PAGE was performed using either a 6 % polyacrylamide gel or a 4-
12% NuPAGE Bis-Tris gradient gel (Invitrogen). 
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2.2.6    Phosphatase treatment 
Flag-CAD was immunoprecipitated from radiolabeled HEK-293 cells as 
described above.  The Flag-resin was washed 2 times with 1 ml of cell lysis buffer 
without the addition of ATP or protease or phosphatase inhibitors to remove any 
remaining phosphatase inhibitors used in previous steps.  The Flag-CAD bound to Flag-
resin then was resuspended in phosphatase buffer (50 mM tricine pH 8.0, 5 mM KCl) and 
placed at 30 °C.  The dephosphorylation of CAD was initiated by adding 20 µl of 1
unit/µl calf intestine alkaline phosphatase (CIP) (Roche).  20 µl of 50 % glycerol (CIP 
suspension buffer) was added to the untreated control samples.  The reaction was stopped 
by adding 1 ml of ice-cold lysis buffer (20 mM Tris-HCl (pH 7.5), 137 mM NaCl2 10% 
glycerol, 5 µg/ml leupeptin, 250 µM phenylmethylsulfonyl fluoride (PMSF) 100 nM 
microcystin, 200 µM Na3VO4, and 2 mM ATP).  The Flag resin-bound CAD was pelleted 
and the supernatant was removed.  The immunoprecipitates were washed again with 1 ml 
of lysis buffer before they were used in CAD activity assays as described above.  To 
determine the degree of dephosphorylation and to map the sites that were 
dephosphorylated, the above procedure was performed with [32P]-labeled Flag-CAD 
isolated from metabolically labeled HEK-293 cells.  The CAD from these samples then 
was separated using SDS-PAGE and the amount of dephosphorylation between the 
control and the CIP treated CAD was analyzed by performing autoradiography on the gel.  
2D-phosphopeptide mapping then was performed on CAD as described below. 
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2.2.7    Kinase Assays 
16 µl of immunoprecipitated Flag-CAD (resuspended 20 mM Tris-HCl (pH 7.5), 
137 mM NaCl2 10% glycerol, 5 µg/ml leupeptin, 250 µM phenylmethylsulfonyl fluoride 
(PMSF) 100 nM microcystin, 200 µM Na3VO4) was combined with 6 µl of ERK kinase 
reaction buffer that had the final concentration of 40 µM ATP 50mM Tris-HCl, 10 mM 
MgCl2, and 2 mM dithiothreitol), 4 µl of [-32P]ATP (10 mCi/ml) and 4 µl of purified 
Erk2 (100 units/µl) (New England BioLabs) (final reaction volume was 30 µl).  The 
reaction was allowed to proceed for 45 min at 37 °C.  The reaction was stopped by 
adding 2X SDS sample buffer.  PKA kinase assays were performed in essentially the 
same manner as the ERK kinase assays, except that PKA buffer (50 mM Tris HCl (pH 
7.5), 10 mM MgCl2), and 500 units of purified PKA catalytic subunit (New England 
BioLabs) was used. 
2.2.8    Trypsin digestion of CAD 
After Flag-CAD was immunoprecipitated as described above, SDS-PAGE was 
performed and the gel was stained with Coomassie.  The gel then was placed in a destain 
solution of 5% methanol and 7% acetic acid and allowed to gently rotate until the Flag-
CAD protein could be visualized.  The destain solution was discarded and the gel was 
washed in water.  The gel bands containing Flag-CAD were excised from the gel and 
chopped into small pieces with a razor blade.  The gel pieces then were added to a 
microfuge tube and the Coomassie stain was removed by adding enough solution A (50 
% acetonitrile and 50 % of 25 mM ammonium bicarbonate (pH 8.0) to cover the gel 
pieces and vortexing the tube for 5-10 min.  Solution A then was removed from the gel 
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pieces and fresh solution A was added.  The gel pieces were allowed to dehydrate by 
setting at room temperature in solution A for approximately 1 hour.  Next, solution A was 
removed and the gel pieces were dried in a speed vacuum microcentrifuge for 
approximately 30 minutes.  20 Wl of 25 mM ammonium bicarbonate containing 0.4 Wg of
sequence grade modified trypsin (Promega) was placed on top of the dried gel pieces.  
The trypsin then was allowed to soak into the gel pieces for 20 minutes before an 
additional 25 mM ammonium bicarbonate (enough to cover the gel pieces) was added.  
The tube then was incubated at room temperature for 18-24 hours.  The supernatant was 
removed and placed into a new microfuge tube.  The tryptic peptides were eluted from 
the gel pieces by adding 50 µl of elution solution (60 % acetonitrile and 5 % formic acid) 
and vortexing every 5 min for 30-45 minutes.  Next, the supernatant was added to the 
previous supernatant and the above elution protocol was repeated.  The combined eluate 
was dried down to approximately 5 µl in the speed-vac.  The peptides then were washed 
twice with water to remove the ammonium bicarbonate.  After the water was removed in 
the speed vacuum microcentrifuge, the peptides were resuspended in 10 µl of the pH 1.9 
buffer (15 % v/v of acetic acid and 5 % v/v of 88 % formic acid).  To determine the 
elution efficiency of the phosphopeptides from the gel (typically around 80 %), the 
amount of radioactivity in the eluate and the remaining gel pieces was determined by 
Cerenkov counting with a scintillation counter. 
2.2.9    Ni-NTA Chromatography 
 After lysing 5 confluent 100 mm tissue culture plates of [32P]-orthophosphate 
metabolically labeled HEK-293 cells transfected with a N-terminal 6X-His-CAD 
construct were lysed in cell lysis buffer (described above), the lysates were centrifuged 
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for 30 min at 100,000 X g.  The supernatant of the cell lysate then was brought up to a 
volume of 10 ml in buffer A (20 mM Tris-HCl, (pH 8.5), 500 mM KCl, 20 mM 
imidazole, 5 mM 2-mercaptoethanol, and 10 % (v/v) glycerol).  A gravity-flow 
chromatography column was filled with 0.5 ml bead volume of Ni-NTA resin (Qiagen).  
The column was equilibrated by allowing 5 ml of buffer A to flow through the resin 
before the supernatant was added to the column.  The column was washed with 8 column 
volumes of buffer B (20 mM Tris-HCl (pH 8.5), 1 M KCl, 5 mM 2-mercaptoethanol, and 
10% (v/v) glycerol).  6X-His-CAD then was eluted from the column using 10 column 
volumes of elution buffer (20 mM Tris-HCl (pH 8.5), 100 mM KCl, 200 mM imidazole, 
5 mM 2-mercaptoethanol, and 10 % (v/v) glycerol).  The eluates were spin concentrated 
using a BIOMAX 100 kDa cutoff 4 ml spin concentrator (Millipore).  These eluates then 
were separated by SDS-PAGE and CAD was trypsin digested as described above. 
2.2.10    Reverse Phase HPLC 
 Gel eluted tryptic peptides were brought up to a volume of 110 µl in 0.1 % HPLC 
grade trifluoroacetic acid (TFA) (Pierce).  The peptides were separated by reverse phase 
chromatography using a Hewlett-Packard HP 1100 Series High Performance Liquid 
Chromatograph (HPLC) System connected to a Vydac C18 column (Cat # 218TP5115).  
The peptides were eluted with a linear gradient of 0-10% buffer B (90 % acetonitrile, 10 
% H2O, and 0.1 % TFA) over the first 10 minutes, from 10 % to 40 % buffer B from 10 
minutes to 45 minutes, and from 40 % to 65 % buffer B from 45 minutes to 65 minutes.  
The flow rate was 0.250 ml/minute and fractions were collected every minute. 
55
2.2.11    2-dimensional phosphopeptide mapping and mass spectrometry 
 The peptides in the pH 1.9 buffer (15 % v/v of acetic acid and 5 % v/v of 88 % 
formic acid) were spotted in the corner of a 10 X 10 cm cellulose, glass-backed thin layer 
chromatography (TLC) plate.  The peptides then were electrophoresed at 1000 V for 25 
minutes in pH 1.9 buffer in a Hunter thin-layer electrophoresis box.  After the TLC plates 
were thoroughly dried, the peptides were separated in the second dimension by ascending 
chromatography by placing the TLC plates in a TLC chamber containing approximately 
104 ml of Scheidtmann buffer (65 ml isobutyric acid, 5 ml pyridine, 3 ml acetic acid, 2 
ml butanol, and 29 ml H2O) (Scheidtmann et al., 1982). After drying the plates, the 
phosphopeptides were imaged by exposing the plates to X-ray film or a phosphoimager 
plate.  The cellulose in the areas on the TLC plate containing the phosphopeptides was 
scraped off the plate.  The peptides were eluted off the cellulose by adding 50 µl of pH
1.9 buffer and vortexing for approximately 1 min.  This elution procedure was repeated.  
The volume of the peptides then was reduced to approximately 5 µl in a speed vac.  
Peptides then were either purified using C18 ziptips (Millipore) following manufactuer’s 
protocol, or directly spotted onto MALDI-mass spectrometer sample target plates.  The 
premixed dihydrobenzoic acid or -cyano-4-hydroxy-cinnamic acid matrices then was 
added to the peptides on the target plate.  The Bruker Daltronics Ultraflex MALDI-
TOF/TOF or the ABI 4700 MALDI-TOF/TOF mass spectrometers operating in positive 
ion mode were used to analyze the mass of the peptides. Phosphatase treatment was 
performed on the MALDI target plate by adding 0.01 units of CIP (Roche) in 50 mM 
ammonium bicarbonate directly to the previously analyzed peptide sample.  15 min later 
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the peptides were analyzed again on the Ultraflex, MALDI-TOF/TOF mass spectrometer 
to identify ions that had an –80 m/z shift (characteristic of a loss of a phosphate group). 
 
2.3    Results 
2.3.1    Mapping of phosphorylation sites in CAD from intact cells 
Considerable speculation into the identity of potential CAD phosphorylation sites 
has been made; however, a definite analysis of these sites has not been performed.  
Moreover, because of its large size, analysis of phosphopeptides from CAD is extremely 
challenging.    To determine the identity of phosphorylated amino acids in CAD from 
intact cells, 6X-His-CAD was expressed and isolated from [32P]-orthophosphate labeled 
human embryonic kidney cells (HEK-293) as described in Materials and Methods.  The 
isolated CAD was trypsin digested, separated by C18 reverse-phase HPLC, and each 
fraction was analyzed on an ABI 4700 MALDI-TOF/TOF mass spectrometer.  The mass 
spectra from a series of three fractions (fractions 48-50) are displayed in Figure 2.1. The 
identity of the CAD peptides that each ion represented was determined by matching them 
to the m/z of the predicted CAD tryptic peptide ions using Protein Prospector 
(http://prospector.ucsf.edu) (Clauser et al., 1999). The peak at m/z 2962.2724 
corresponded to a singly charged CAD peptide Trp1812-Arg1838 containing a single 
phosphate group.  Additionally, the peak at 3090.3121 corresponded to the singly 
charged CAD peptide Lys1811-Arg1838 containing a phosphate group.  MS/MS analysis of 
the 3090.3121 ion was performed, and although not conclusive, the data suggested that 
the peptide was 1811KWPQGAVPQPPPS*APATTITTTPERPRR1838, with the asterisk 
representing the putatively phosphorylated Ser residue. 
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To further examine the identity of phosphorylated amino acids in CAD from 
intact cells, Flag-CAD was immunoprecipitated from [32P]-orthophosphate labeled 
human embryonic kidney cells (HEK-293).  CAD tryptic peptides were analyzed by 2D 
TLC as described in Materials and Methods.  As seen in Fig. 2.2A, there were four major 
phosphopeptide spots (labeled 1-4) observed in CAD from HEK-293 cells.  The 
phosphopeptides were scraped from the TLC plate, eluted from the scrapings, and 
analyzed by MALDI-MS and tandem MS.  The MS spectrum from the eluate from spot 4 
contained a peak at m/z 1696.7708, which corresponded to charged CAD peptide Ala1855-
Lys1869 containing a single phosphate group. MS/MS was performed and the sequence of 
this peptide was determined to be IHRAS	DPGLPAEEPK (1855-1869), where the 
asterisk represents the phosphorylated serine 1859 residue (Figure 2.2B).  The eluate 
from spot 1 was determined to contain the phosphopeptide AS	 DPGLPAEEPK (1857-
1869), which was the same peptide found in spot 4, except that it had three less amino 
acids, corresponding to trypsin cleavage.  Hence, spot 4 was determined to contain a 
missed trypsin cleavage peptide.  Additionally, MALDI-MS spectrum of the eluate from 
spot 3 contained a peak at m/z 1526.531, which corresponded to the singly charged CAD 
peptide Ala1769-Lys1780 containing a single phosphate group (Figure 2.3).  While the 
MS/MS data of this ion was inconclusive, the treatment of this peptide with phosphatase 
caused the peak to be shifted by -80 m/z (the m/z of a phosphate moiety) to 1446.536, 
which matched the m/z of the unphosphorylated peptide (Figure 2.3).  Since the sequence 
of this peptide is 1769ARWTPFEGQKVK1780, Thr1772 is the only residue that can be 
phosphorylated. 
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To corroborate the mass spectrometry data, we mutated Ser1859 to Ala1859 
(S1859A) and transfected HEK-293 cells with either WT Flag CAD or the S1859A CAD 
mutant.  2D phosphopeptide maps were run to compare the phosphopeptide patterns from 
wild type (WT) CAD and the alanine mutant.  As observed in Fig. 2.2C, spots 1 and 4 
were absent in the 2D maps from the S1859A CAD mutant when compared to WT CAD.  
This confirmed our data from Fig. 2.2B that spots 1 and 4 contain the peptide with 
pSer1859. We are currently making the Thr1772 to Ala1772 (T1772A) mutant to corroborate 
the mass spectrometry data displayed in Figure .2.3. 
2.3.2    Effect of CAD phosphorylation on enzyme activity and allosteric regulation 
Since CAD from HEK-293 cells growing in 10 % serum media was 
phosphorylated on multiple sites (Fig. 2.2A) and previous evidence suggested that the 
phosphorylation of CAD increased the allosteric activation by PRPP (Carrey et al., 1985; 
Graves et al., 2000; Sigoillot et al., 2002b), we hypothesized that dephosphorylation 
would decrease the allosteric activation or catalytic activity of CAD.  
Immunoprecipitated Flag-CAD from [32P]-orthophosphate labeled HEK-293 cells was 
incubated with or without calf intestinal phosphatase (CIP).  As seen in Fig. 2.5A, CIP 
treatment reduced the total amount of radioactive phosphate in into CAD.  Furthermore, 
2D phosphopeptide analysis of CIP-treated or control CAD demonstrated that CIP 
treatment reduced the phosphorylation of phosphopeptides 1-4 (Figure 2.5B)  To 
determine if the reduction in CAD phosphorylation affected enzymatic activity, we 
performed CAD activity assays on immunoprecipitated Flag-CAD treated with or without 
CIP for 15, 30 or 45 minutes.  15 minutes after the addition of CIP, CAD activity was 
reduced by approximately 40 % compared to control.  Treatment with CIP resulted in a 
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time-dependent loss of CAD activity that paralleled the loss of CAD phosphorylation 
(Fig.2.5C).  Interestingly, CIP treatment did not affect the ability of PRPP to stimulate 
CAD activity (Fig 2.5D). 
2.3.3    Ser1406 and Ser1859 phosphorylated by PKA in intact cells 
Previous studies showed that CAD was phosphorylated by PKA in vitro on 
residues Ser1406 and Ser1859 (Carrey et al., 1985).  CAD has also been reported to 
autophosphorylate (Sigoillot et al., 2002a).  To determine if any of the sites observed in 
the 2D maps were from PKA phosphorylation or autophosphorylation, 2D-
phosphopeptide mapping was performed on Flag-CAD incubated with either [-32P]ATP 
alone or with the purified catalytic subunit of PKA.  As shown in Fig. 2.6A, spots 1 and 
4, which represented pSer1859 peptide (as shown in Figure 2.2), was phosphorylated.  
Additionally, we observed a new phosphopeptide spot (labeled spot 5) present in CAD 
phosphorylated by PKA that was not seen in the 2D maps from CAD isolated from HEK-
293 cells (Figure 2A).  No evidence of CAD autophosphorylation was observed in these 
experiments. 
To investigate the phosphorylation of CAD by PKA in vivo, WT Flag-CAD was 
immunoprecipitated from lysates from [32P]-orthophosphate labeled HEK-293 cells that 
had been treated with vehicle (DMSO) or 20 µM forskolin for 15 minutes prior to cell 
harvesting and 2D-phosphopeptide mapping was performed.  As shown in Figure 5B, 
forskolin treatment increased the phosphorylation of Ser1859 (spot 4) and induced the 
phosphorylation of spot 5.  To determine if spot 5 contained the putative PKA 
phosphorylation site pSer1406 (Carrey et al., 1985), we mutated Ser1406 to Ala1406 
(S1406A) and transfected this mutant into HEK-293 cells.  Cells were metabolically 
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labeled and treated with or without forskolin as described above.  As observed in Figure 
2.6C, spot 5 was absent from the forskolin-treated sample; whereas, it was observed in 
WT CAD (Figure 2.6B).  This data demonstrated that spot 5 represented the 
phosphopeptide containing pSer1406. Since we observed the Ser1859 peptide was 
phosphorylated in HEK-293 without forskolin stimulation, we hypothesized that there 
might be a basal level of PKA activity in HEK-293 cells that resulted in the 
phosphorylation of Ser1859. To test this, we treated [32P]-orthophosphate metabolically 
labeled HEK-293 cells with the PKA kinase inhibitor, H89.  2D-phosphopeptide mapping 
then was performed on the isolated Flag-CAD.  As shown in Figure 2.6B, H89 caused a 
significant reduction in the phosphorylation of Ser1859, confirming that this site was 
phosphorylated by PKA, or another H89-sensitive kinase. 
2.3.4    Thr456 is not a major ERK-mediated phosphorylation site in CAD 
Since phosphorylated Thr456 was not observed in our analysis of CAD 
phosphorylation  (Fig. 2.2), we designed experiments to reevaluate whether Thr456 was a 
major CAD phosphorylation site.  Since ERK had been reported to phosphorylate CAD 
in vitro on Thr456 (Graves et al., 2000), we performed 2D-phosphopeptide mapping on 
WT Flag-CAD or T456A Flag-CAD that was incubated with either [-32P]ATP alone or 
in the presence of recombinant active ERK2.  Erk2 activity was verified by MBP 
phosphorylation (data not shown).  We were unable to detect phosphopeptides from WT 
Flag-CAD or T456A Flag-CAD incubated with [-32P]ATP alone; however, both WT and 
T456A CAD contained numerous phosphopeptides when incubated with ERK2 (Fig. 
2.7A).  Surprisingly, none of the phosphopeptide spots were reduced in the 2D maps 
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from T456A CAD (Fig. 2.7A).  This data suggested that Thr456 was not a major ERK-
induced CAD phosphorylation site in vitro.
To determine if we could detect the ERK-induced CAD phosphorylation site in 
vivo, we transfected HEK-293 cells with WT-Flag CAD and serum-starved the cells 
overnight.  The cells were radiolabeled with [32P]-orthophosphate and incubated with or 
without 150 ng/ml of EGF for 15 minutes to activate ERK (described in Materials and 
Methods).  ERK activation was verified by immunoblotting for active ERK (Figure 
2.7B).  CAD was immunoprecipitated and 2D-phosphopeptide mapping was performed.  
While we observed a robust phosphorylation of ERK (Fig. 2.7B right), indicating that 
ERK was activated under these conditions, the 2D maps from CAD isolated from the 
EGF-treated cells showed no apparent change in phosphorylation when compared to 
CAD isolated from the unstimulated control cells.  This result suggested that CAD was 
not a substrate of ERK in intact cells under these conditions. 
However, to further investigate if ERK phosphorylated CAD basally, we 
examined the affect of a MEK-1 inhibitor known to prevent ERK activation (U0126).  
U0126 was added to HEK-293 cells during the 3 hour incubation with [32P]-
orthophosphate and CAD was immunoprecipitated and 2D-phosphopeptide mapping 
performed.  As seen in Fig. 2.7C (lower panel), U0126 reduced ERK phosphorylation as 
expected.  However, no reduction in the phosphorylation of any of the phosphopeptides 
from CAD was observed when compared to CAD isolated from control and U0126 
treated cells (Fig. 2.7C, upper panel). 
 Although ERK activation did not increase the phosphorylation of Thr456, there 
remained a possibility that a peptide containing pThr456 was present in the remaining 
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phosphopeptide spots.  To test this, WT Flag-CAD or T456A Flag-CAD was transfected 
into HEK-293 cells, the cells were radiolabeled with [32P]-orthophosphate, and 2D-
phosphopeptide mapping was performed.  As shown in Figure 2.7D, spots 1-4 were 
present in the maps from WT CAD and T456A CAD, suggesting that pThr456 was not a 
major CAD phosphorylation site in these cells. 
In addition to investigating the effects of EGF stimulation on CAD 
phosphorylation, we wanted to determine if CAD was phosphorylated by serum-induced 
kinases, which contains numerous growth factors.  HEK-293 cells were transfected with 
WT Flag-CAD, placed in low serum for 18 hours, labeled with  [32P]-orthophosphate, and 
stimulated with 10 % FBS for the indicated times (Figure 2.8).  As shown in Figure 2.8, 
no increase in radioactivity incorporation into spots 1-4 occurred at the 10 min, 30 min, 
or 60 min time points when compared to the control.  Interestingly, the overall 
radioactivity incorporation into all of the spots appeared to be slightly lower in both the 
10 min and 30 min time points when compared to the 0 min and 60 min time points.  
Additionally, two minor phosphopeptide spots (indicated by arrows) were observed in the 
0 min and 60 min time points (Figure 2.8).    
It has been reported that the enhanced allosteric activation of CAD by 
phosphorylation of Thr465 by ERK in a human breast cancer cell line is the potential cause 
for the elevated level of pyrimidine synthesis in these cells.  Additionally Guy and 
colleagues reported that pThr456 CAD is localized to the insoluble nuclear fractions of 
numerous different cell lines.  The basis for the conclusions in both of these studies came 
from the data collected using an antibody designed to specifically recognize the pThr456 
residue.  However, the specificity of this antibody has not been reported.  Since our data 
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suggested that pThr456 was not a major phosphorylation site in CAD, we designed two 
experiments to test the specificity of the pThr456 antibody.  First, we performed 
immunoblots using lysates from CAD-deficient G9C cells (expressing either WT-CAD, 
the T456A mutant, or the empty vector (PCDNA 3.1) (described in (Graves et al., 2000)).  
The separation of soluble and insoluble cellular fractions was performed exactly as 
described earlier (Sigoillot et al., 2005).  The proteins were separated by SDS-PAGE and 
an immunoblot was performed using the pThr456 antibody (Santa Cruz Biotechnology).  
We detected a protein that ran on SDS-PAGE at a molecular weight similar to where 
CAD was normally observed (240 kDa) in the insoluble fractions from G9C cells 
transfected with WT-CAD.  Additionally, we observed the same band in the G9C cells 
transfected with T456A CAD or the empty vector (Figure 2.9A).  This suggested that this 
antibody was not specific for the Thr456 phosphorylation site.  To further investigate the 
specificity of the anti-phospho Thr456 antibody, we immunoprecipitated WT Flag-CAD or 
T456A Flag-CAD from HEK-293 cells as described in Materials and Methods. SDS-
PAGE was performed and western blots were performed.  By immunoblotting with an -
Flag antibody we demonstrated that both WT and T456A Flag-CAD were expressed and 
immunoprecipitated at similar levels (Figure 2.9B lower panel).  As seen in the top panel 
of Figure 2.9B, the -pThr456 antibody reacts with either CAD or a protein that has an 
identical molecular weight to CAD in the lysates (input) and immunoprecipitates from 
both WT-Flag CAD and T456A Flag-CAD.  Therefore, this data strongly suggests that 
the pThr456 antibody from Santa Cruz that was used in three prior studies (Kotsis et al., 
2007; Sigoillot et al., 2005; Sigoillot et al., 2004), does not bind specifically to 
phosphorylated Thr456 CAD. 
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2.3.5    Forskolin stimulation of PKA in HEK-293 cells decreased CAD activity  
Carrey and colleagues showed that PKA phosphorylation of CAD in vitro 
abolished UTP inhibition of enzymatic activity (Carrey et al., 1985).  Furthermore, Guy 
and colleagues reported that there was a correlation between an increase in PKA activity 
and an increase in total serine phosphorylation of CAD in cells as they reached growth 
arrest (Sigoillot et al., 2002b).  Moreover, the increase in CAD serine phosphorylation 
correlated with a decrease in the PRPP stimulation of CAD activity (Sigoillot et al., 
2002b).  To evaluate the effect of PKA activation in intact cells on CAD enzymatic 
activity and allosteric function, we stimulated HEK-293 cells transfected with Flag-CAD 
with forskolin or with the vehicle control DMSO.  Since we observed increased CAD 
phosphorylation using this same treatment protocol (Figure 2.6B), we assumed that CAD 
phosphorylation was also increased in this experiment.  Flag-CAD was 
immunoprecipitated and enzymatic activity assays were performed using multiple 
concentrations of ATP. Activation of PKA did not affect the affinity of CAD for ATP; 
however, there was a small decrease in the CPSase II activity isolated from forskolin 
treated cells when compared to compared CAD isolated from DMSO treated cells (Figure 
2.10A).  Additionally, there was a slight decrease in PRPP stimulation from CAD 
isolated from forskolin-treated cells when compared to CAD from DMSO treated cells 
(Figure 2.10B). 
2.3.6    Effect of mutating CAD phosphorylation sites to alanines on the enzymatic 
activity and allosteric regulation of CAD 
To begin to address potential importance of the phosphorylation of specific 
residues on CAD enzymatic function, we performed CPSase II activity assays on the 
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phosphorylation site mutants.  WT Flag-CAD, T456A Flag-CAD, T1037E Flag-CAD, 
S1406A Flag-CAD, and S1859A Flag-CAD were expressed in HEK-293 cells and 
immunoprecipitated as described in Materials and Methods.  CPSase II enzyme activity 
assays were performed on immunoprecipitated Flag-CAD constructs as described in 
Materials and Methods.  As shown in Figure 2.11A, both WT Flag-CAD and S1859A 
Flag-CAD displayed an almost identical increase in activity as the ATP concentration 
was increased.  When compared to both the WT-Flag CAD and S1859A-Flag CAD 
mutants, the T456A Flag CAD mutant had an approximate 6-fold reduction in CAD 
activity at the 20 mM ATP concentration.  Additionally, the activity of the S1406A and 
T1037E Flag-CAD mutants was reduced approximately 20-fold when compared to the 
activity of both WT and S1859A Flag-CAD.  Interestingly, 500 µM of PRPP stimulated 
the CPSase II activity of each of these Flag-CAD mutants to a level similar to that 
observed with WT Flag-CAD (Figure 2.11B). 
While all of the mutants described above were activated by PRPP to a similar 
degree as wild-type Flag-CAD, interestingly, the CPSase II activity of the T1037A CAD 
mutant showed a significantly greater increase.  To investigate this effect further, we 
performed a PRPP dose-response experiment.  As seen in Figure 2.12B, the activity of 
the T1037A mutant was increased 2000 % over no ligand by 125 µM PRPP, while the 
activity of WT-CAD increased 1000 % at the same PRPP concentration.  At 500 µM
PRPP, T1037A was stimulated approximately 3-fold higher than WT-Flag CAD.  
Furthermore, 500 µM appeared to be the saturating concentration of PRPP for both WT 
Flag-CAD and T1037A Flag-CAD since neither displayed a further increase in CPSase II 
activity when the PRPP concentration was increased to 2 mM (Figure 2.12B).  When the 
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CPSase II activity of WT-Flag CAD and T1037A Flag-CAD were measured as a function 
of increasing ATP concentrations, it was observed that the T1037A mutant had less 
CPSase II activity than WT-Flag CAD (Figure 2.12A).  Thus these results suggested that 
mutation of Thr1037 affected both the PRPP-stimulation and basal CPSase II activity. 
2.3.7    A caffeine sensitive kinase phosphorylates Ser1859 
Since CAD was phosphorylated on Ser1859, Thr1772, and on an unknown 
phosphopeptide represented by spot 2 (Figure 2.2A and 2.3), we wanted to determine the 
identity of the kinase(s) responsible for phosphorylating these sites.  We hypothesized 
that the ionizing radiation from the [32P]-orthophosphate might be inducing a checkpoint 
response, thereby activating the ATM/ATR and Chk1/2 kinases.  A common drug used to 
inhibit ATM and ATR is caffeine (Sarkaria et al., 1999).  Therefore, to test the hypothesis 
that ATM/ATR or their downstream substrate kinases Chk1/2 were leading to the 
phosphorylation of Ser1859, Thr1772, and/or the phosphopeptide spot 2, we treated cells 
labeled with [32P]-orthophosphate with 5 mM caffeine.  Interestingly, 2D phosphopeptide 
maps of the immunoprecipitated Flag-CAD from the caffeine treated cells demonstrated 
that Ser1859 phosphorylation was significantly reduced when compared to Flag-CAD from 
control cells (Figure 2.13).  Thus this result suggests that a caffeine sensitive kinase 
phosphorylates Ser1859.
2.3.8    14-3-3 forms a protein-protein interaction with CAD 
 CAD was identified as a 14-3-3 binding protein in a large scale mass 
spectrometry screen designed to detect 14-3-3 binding proteins (Meek et al., 2004).  We 
sought to confirm this interaction and to determine if pSer1406 (a predicted 14-3-3 binding 
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site according to the scansite sequence match program (Obenauer et al., 2003) bound 14-
3-3. To confirm that 14-3-3 could bind to CAD and to determine if Ser1406 was 
necessary for interaction with 14-3-3, we incubated the lysates from HEK-293 cells 
transfected with either WT Flag-CAD, or S1406A Flag-CAD, with glutathione agarose 
beads bound to either GST alone, or GST-14-3-3.  As seen in Figure 2.14, GST-14-3-3 
bound to both WT Flag-CAD and S1406A CAD.  While this data confirmed that 14-3-3 
zeta bound to CAD (Meek et al., 2004), it suggested that a phosphorylation site in CAD 
other than Ser1406 was responsible for this protein-protein interaction. 
2.4     Discussion 
2.4.1      Identification of CAD phosphopeptides 
Although CAD has been reported to be phosphorylated on several residues, this is 
the first comprehensive investigation to identify the phosphorylation sites in CAD 
isolated from intact cells.  By using mass spectrometric analysis and 2D-phosphopeptide 
mapping, we determined there are a minimum of five major tryptic phosphopeptides in 
CAD (Figure 2.2A and 2.6B).  Phosphopeptide spots 1 and 4 were identified as 
containing pSer1859, spot 5 is the phosphopeptide containing pSer1406, and spot 3 likely 
contains pThr1772. While we have yet to identify the phosphopeptide in spot 2 (Figure 
2.2), we did determine that this spot did not contain the previously proposed 
phosphorylated residues pThr456, pThr1037, or the putative CAD phosphorylation site 
Ser1823 that we found by other methods (Figures 2.1, 2.4, and 2.7.D).  Furthermore, while 
the large-scale phosphorylation site analysis identified the CAD residues Ser1900, pSer1920,
pSer1928, and pThr1933 as in vivo CAD phosphorylation sites (Olsen et al., 2006), these 
phosphorylated residues were not found in phosphopeptide spot 2. (Figure 2.4).  While 
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this implies that there are additional unknown phosphopeptides in CAD, it does not 
necessarily demonstrate that the above phosphopeptides do not exist.  One explanation 
for us not observing these phosphopeptides with the 2D phosphopeptide maps is that 
these sites are already maximally phosphorylated when the cells are metabolically labeled 
with [32P]-orthophosphate and consequently do not incorporate radioactive phosphate.  
Furthermore, it is possible that low stoichiometry of phosphorylation prevents these 
phosphopeptides from appearing as major spots on our phosphopeptide maps.  Indeed, we 
sometimes observed faint phosphopeptide spots as indicated by the arrows in Figures 
2.2C, and 2.8 that could possibly represent low levels of these minor phosphopeptides.  
To investigate the importance of these major CAD phosphopeptides (Figure 2.1) 
on CPSase II activity, we dephosphorylated CAD immunoprecipitated from HEK-293 
cells with a phosphatase and measured enzymatic activity (Figure 2.5).  Since we 
observed a reduction in the phosphorylation of all four phosphopeptides and a decrease in 
CPSase II activity after phosphatase treatment, we concluded that these phosphopeptides 
were important for catalytic activity.  Furthermore, since spots 1 and 4 represent the 
phosphopeptide containing Ser1859 (Figure 2.2) and the phospho-null S1859A mutant did 
not affect CPSase II activity (Figure 2.11A), we have hypothesized that Thr1772 (spot 3) 
and/or the unknown phosphopeptide in spot 2 are important for the CPSase II catalytic 
activity.   
2.4.2       PKA phosphorylation of CAD 
Our studies were designed to determine the sites that were phosphorylated in 
CAD by PKA in HEK-293 cells.  While we determined that PKA induced the 
phosphorylation of Ser1406 and Ser1859, we demonstrated that there was a high basal level 
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of Ser1859 phosphorylation in HEK-293 cells growing in normal growth media (Figures 
2.2 and 2.6).  When H89, a chemical that inhibits PKA activity, was added to the cells, 
the phosphorylation of Ser1859 dropped to almost undetectable levels (data not shown).  A 
potential explanation for these results is that there is a low level of PKA activity in HEK-
293 cells (which was observed by Higgins and Graves (unpublished data)), which 
phosphorylates Ser1859, and that only a significant increase in PKA activity induced by 
forskolin allows for the phosphorylation of Ser1406. However, since H89 is a non-specific 
kinase inhibitor (Davies et al., 2000), another explanation is that Ser1859 can be 
phosphorylated by both PKA and another H89-sensitive kinase that is active in HEK-293 
cells.  Indeed, we discovered phosphorylation was also inhibited by caffeine (Figure 
2.13), suggesting a potential role for the kinases ATM/ATR.  It is interesting to speculate 
that phosphorylation of CAD by these kinases may relate to the function of the 
interaction of the checkpoint protein hRad9 with CAD (Lindsey-Boltz et al., 2004) 
(described in Chapter III). 
The phosphorylation of CAD was reported to be important in modulating the 
allosteric regulation and enzyme activity of this multifunctional protein.  Early work by 
Elizabeth Carrey and colleagues suggested that in vitro phosphorylation of CAD by PKA 
on residues Ser1406 and Ser1859 increased CAD activity in cells since it caused a decrease 
in UTP “feedback” inhibition of CAD.  Guy and colleagues observed that the PKA 
phosphorylation of CAD caused a decrease in the PRPP-induced activation of CPSase II 
activity.  As seen in Figure 2.11, our data demonstrate that forskolin induces both a slight 
decrease in CAD activity at high ATP concentration (20 mM) and a slight decrease in 
PRPP activation.  At lower ATP concentrations, which are closer to physiological 
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amounts (2-5 mM ATP), forskolin did not affect CPSase II activity.  Therefore, it has to 
be questioned whether or not the affect of forskolin-induced PKA activation on CPSase II 
activity is physiologically relevant.  Furthermore, while the S1859A mutant did not affect 
CPSase II activity, the S1406A mutant significantly decreased enzymatic activity at all 
concentrations of ATP tested (Figure 2.11A).  Interestingly, the allosteric activation of 
the S1406A CAD mutant activity by PRPP was similar to WT CAD, suggesting that 
allosteric activation by this ligand was unaffected (2.11B).  Since the phosphorylation of 
this site by forskolin induced a slight decrease in CPSase II activity, the phosphorylation 
null alanine mutant would not be expected to decrease CPSase II activity.  Therefore, it is 
possible that the S1406A mutation affects the catalytic activity in a manner not related to 
the loss of phosphorylation of this residue in the S1406A mutant.   
2.4.3       ERK phosphorylation of CAD 
Previous reports suggest that Thr456 was phosphorylated in vitro by ERK (Graves 
et al., 2000).  However, it was not determined if this was the major site of ERK 
phosphorylation in CAD.  Surprisingly, our 2D-phosphopeptide maps from WT-Flag 
CAD and T456A-Flag CAD phosphorylated in vitro by ERK (Figure 2.7A) showed no 
difference, suggesting that Thr456 was not a major ERK-induced CAD phosphorylation 
site.  Although in our mass spectrometry analysis, we observed a peptide consistent with 
the phosphorylation of Thr456 (Jun Han, unpublished), our 2D-phosphopeptide data does 
not support the conclusion that Thr456 is a major phosphorylation site.  Instead our studies 
suggest that multiple residues in CAD can be phosphorylated by ERK in vitro. An 
alternative explanation for Thr456 not being observed is that it was already phosphorylated 
in CAD isolated from HEK-293 cells.  To address this concern, CAD isolated from HEK-
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293 cells was treated with a phosphatase before being phosphorylated in vitro with ERK.  
We observed that there was the same amount of ERK-mediated phosphorylation on the 
phosphatase-treated CAD compared to the CAD not treated with a phosphatase (data not 
shown).   
Although it had previously been reported that CAD was phosphorylated by ERK 
on Thr459 in vivo (Sigoillot et al., 2002a), our data in Figure 2.7B-D demonstrated that 
while EGF-stimulation induced a robust activation of ERK in HEK-293 cells, no increase 
in CAD phosphorylation was observed. Additionally, since there was some basal level of 
ERK activity in HEK-293 cells even after serum-starvation (Figure 2.7C), it could be 
argued that this active ERK could cause Thr456 to be already maximally phosphorylated 
before EGF-stimulation.  To determine if this possibility was correct, we treated HEK-
293 cells with the MEK-1 inhibitor U0126 to reduce the basal ERK activity.  U0126 
inhibited ERK, but did not reduce the phosphorylation of the CAD peptides represented 
on the 2D phosphopeptide map.  Therefore, taken together, our data presented in Figure 
2.7 clearly demonstrated that while CAD was phosphorylated by ERK on multiple sites 
in vitro, the activation of ERK in HEK-293 cells did not lead to the phosphorylation of 
CAD.  This data is in contrast to the reports by Guy and colleagues that Thr456 was 
phosphorylated in vivo by ERK (Sigoillot et al., 2003; Sigoillot et al., 2002b; Sigoillot et 
al., 2007; Sigoillot et al., 2005; Sigoillot et al., 2004).  The conclusion that ERK was 
phosphorylated on Thr456 by ERK in vivo by these authors was based on experiments 
using an antibody designed to recognize the phosphorylated Thr456 CAD residue 
(Sigoillot et al., 2005).  However, this antibody was not shown to be specific for 
phosphorylated Thr456 and our data strongly demonstrates that this antibody is not 
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specific for pThr456 CAD (Figure 2.9).  Therefore, the conclusions from studies using this 
antibody (Kotsis et al., 2007; Sigoillot et al., 2007; Sigoillot et al., 2005; Sigoillot et al., 
2004) are highly questionable. 
While our data (Figure 2.7) demonstrated that CAD was not phosphorylated by 
ERK in HEK-293 cells, a recent study by Guy and colleagues reported that the 
phosphorylation of CAD by PKA prevented the phosphorylation of CAD by ERK.  Since 
there was the possibility that we did not observe ERK-induced CAD phosphorylation 
because of PKA activity in these cells, we pretreated metabolically labeled HEK-293 
cells with the PKA inhibitor H89 before stimulating them with EGF.  While H89 
significantly decreased CAD phosphorylation, EGF did not induce CAD phosphorylation 
(data not shown). 
2.4.4     EGF stimulation of CAD phosphorylation 
While it was reported that EGF induced the phosphorylation of CAD residues 
Ser1900, Ser1920, Ser1928, and Thr1933 in HeLa cells, as discussed above, we did not observe 
significant EGF-induced CAD phosphorylation in HEK-293 cells.  Two major 
differences exist between these two studies.  First, different cell types were used.  The 
EGF-induced kinase in HeLa cells that is responsible for CAD phosphorylation may not 
be regulated in HEK-293 cells.  Additionally, previous reports have suggested that there 
are CAD phosphorylation sites that inhibit the phosphorylation at other CAD sites (Kotsis 
et al., 2007; Sigoillot et al., 2007).  Therefore, CAD may be phosphorylated on a residue 
in HEK-293 cells that prevents EGF-induced phosphorylation, while CAD in the HELA 
cells is not phosphorylated on this inhibitory residue. The second major difference 
between these two studies was the methods used to identify phosphopeptides.  The mass 
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spectrometry method used by Mann and colleagues might be more sensitive than our 
method, allowing for the detection of minor CAD phosphorylation sites that we were 
unable to detect.  
2.4.5     Autophosphorylation of CAD 
As previously described, a study reported that CAD autophosphorylated on 
Thr1037 (Sigoillot et al., 2002a).  Since CAD is not a kinase, this was a controversial 
finding.  However, we were unable to detect any autophosphorylation on 
immunoprecipitated CAD from HEK-293 cells in our in vitro kinase assays (Figures 
2.6A and 2.7A).  A possible explanation for the discrepancies between our study and the 
one performed by Guy and colleagues is that what was reported to be 
autophosphorylation, was actually phosphorylation induced by a contaminating kinase in 
their isolated CAD.  Another potential explanation is that we did not observe the 
autophosphorylation because we did not use high enough ATP concentrations in our 
kinase assays. However, this seems unlikely since they reported autophosphorylation 
using 50 µM ATP in their kinase assays and we used 40 µM ATP.    
While our data suggest that Thr1037 is not an autophosphorylation site, and we did 
not detect the phosphorylation of Thr1037 on our 2D phosphopeptide maps, we did acquire 
data using the recently described technique of titanium dioxide phosphopeptide 
enrichment (reviewed in Bodenmiller et al., 2007) that suggested that Thr1037 was 
phosphorylated in CAD from HEK-293 cells (data not shown).  Interestingly, we 
observed that while the T1037A mutant slightly reduced CPSase II activity, it displayed a 
significant increase in the fold-stimulation induced by PRPP (Figure 2.12B). 
74
2.4.6     14-3-3 interaction with CAD 
Additionally, we have confirmed that 14-3-3 binds to CAD (Meek et al., 2004).  
Since 14-3-3 typically binds to phosphorylated Ser/Thr residues in proteins (Aitken, 
2006), and pSer1406 matched a putative 14-3-3 binding according to the scansite sequence 
match program (Obenauer et al., 2003), we hypothesized that the phosphorylation of 
Ser1406 mediated the interaction of CAD with 14-3-3.  However as seen in figure 2.14, 14-
3-3 still bound to the S1406A Flag-CAD.  While the amino acid sequence surrounding 
the other phosphorylation sites do not match known 14-3-3 binding consensus sequences, 
there are reports of novel 14-3-3 binding consensus sites (Ganguly et al., 2005; Shikano 
et al., 2005).  Furthermore, it was shown that PKA phosphorylated a Thr residue in one of 
these novel 14-3-3 binding sequences (Ganguly et al., 2005).  Therefore, it is interesting 
to speculate that the function of PKA phosphorylation of Ser1859 might be to facilitate the 
binding of 14-3-3 to CAD. Additionally, since there are proteins that bind 14-3-3 in a 
phosphorylation-independent manner (Clark et al., 2004; Macdonald et al., 2005), there is 
a possibility that the phosphorylation of CAD does not regulate the interaction with 14-3-
3. 
2.4.7       Conclusion 
In conclusion, we have demonstrated that there are four major phosphopeptides 
observed on our 2D phosphopeptide maps of Flag-CAD isolated from HEK-293 cells. 
While spots 1 and 4 represent pSer1859, and spot 3 represent Thr1772, the identity of the 
phosphopeptide in spot 2 remains unknown.  However, our 2D-phosphopeptide maps of 
our Ser/Thr to Ala CAD mutants demonstrate that spot 2 does not represent previously 
reported putative CAD phosphorylation sites (Olsen et al., 2006; Sigoillot et al., 2002a).  
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Our phosphatase treatment and activity data suggest that Thr1772 and/or the 
phosphopeptide represented by spot 2 are important for CPSase II activity.  The 
mechanism by which the phosphorylation of CAD modulates CPSase II activity needs to 
be investigated.  One possibility is that the phosphorylation increases the affinity of 
CPSase II for ATP.  Additionally, since the functional unit of CAD is a hexamer 
(Coleman et al., 1977; Lee et al., 1985; Qiu and Davidson, 2000), the phosphorylation of 
CAD may function to enhance CPSase II activity by facilitating hexamer formation. In 
fact, precedence for this role of phosphorylation in a pyrimidine synthetic enzyme was 
demonstrated by Carman and colleagues.  They observed that the dephosphorylation of 
CTP synthetase isolated from Saccharomyces cerevisiae prevented the formation of the 
active CTP synthetase tetramer.  Additionally, the phosphorylation of CTP synthetase 
with PKA and PKC facilitated the tetramerization of this enzyme (Pappas et al., 1998). 
A fifth phosphopeptide (spot 5), which represents Ser1406, appears after HEK-293 
cells are stimulated with forskolin.  Moreover, CPSase II activity and allosteric activation 
by PRPP are only minimally reduced after forskolin treatment.  Furthermore, while Thr456 
and Thr1037 were not identified as a major phosphopeptides in CAD, the T1037A 
mutation caused a significant increase in the PRPP stimulation of CPSase II activity, and 
the T456A mutation significantly inhibited CPSase II activity.  While we determined that 
ERK phosphorylated CAD on numerous sites in vitro, CAD was not a substrate for ERK 
in HEK-293 cells in our experimental conditions.  Therefore, the model whereby ERK 
regulates the cellular levels of pyrimidines by phosphorylating CAD and increasing 
CPSase II activity (Sigoillot et al., 2003; Sigoillot et al., 2002b; Sigoillot et al., 2005; 
Sigoillot et al., 2004) needs to be reevaluated. 
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Other functions of CAD phosphorylation could be the mediation of the interaction 
of CAD with the hRad9 protein (which is described in Chapter III), or the regulation of 
CAD nuclear localization.  In fact, Ser1406 is located in the sequence of mammalian CAD 
that corresponds to the nuclear localization sequence in yeast URA2 (Nagy et al., 1989).  
Since the phosphorylation of residues within nuclear localization sequences can regulate 
protein entry into the nucleus (reviewed in Jans and Hubner, 1996), the phosphorylation 
of CAD Ser1406 might cause CAD to be transported into the nucleus. 
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Figure 2.1.  Identification of the tryptic-CAD phosphopeptide 1811Lys-Arg1838. His-
CAD was isolated from HEK-293 cells and trypsin digested as explained in Materials and 
Methods.  The tryptic peptides were separated by C18 reverse-phase HPLC, and each 
fraction was analyzed by the ABI 4700 MALDI-TOF/TOF mass spectrometer as 
described in Materials and Methods.  The three mass spectra above were gathered from 
HPLC fractions 48, 49, and 50.  The CAD peptide that each ion represented was 
determined by matching them to the m/z of the predicted CAD tryptic peptide ions using 
Protein Prospector (http://prospector.ucsf.edu) (Clauser et al., 1999).  The peak in 
fraction 48 at m/z 3090.3121 corresponded to the singly charged peptide Lys1811-Arg1838 
containing a single phosphate group.  The peak at m/z 2962.22724 in fraction 48 
corresponded to Trp1812-Arg1838 containing a single phosphate group.  We observed both 
of these phosphopeptide ions in fraction 49, in addition to the peaks at m/z 2882.2306 
and m/z 3010.3875, which corresponded to the Trp1812-Arg1838.
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Figure 2.2.  Identification of Ser1859 as a phosphorylation site in CAD isolated from 
HEK-293 cells.  (A) HEK-293 cells were transfected with Flag-CAD and maintained in 
10% FBS.  24 hours after transfection, the cells were labeled with from [32P]-
orthophosphate.  Lysates were prepared and Flag-CAD was isolated and trypsin digested 
in the gel as described in Materials and Methods.  2D-phosphopeptide mapping then was 
performed by separating the tryptic peptides on a cellulose backed TLC plate in two 
dimensions.  The TLC plates then were exposed to film to identify the area containing 
phosphopeptides.  (B) Spot four (A) was scraped and the peptides were analyzed using 
the 4700 (ABI) MALDI-TOF/TOF mass spectrometer.  A peak at m/z of 1696.7708 on 
the MS spectrum corresponded to the predicted m/z of the singly charged Ala1855-Lys1869 
peptide with the addition of one phosphate group (data not shown).  This peptide was 
fragmented using CID and the fragment ions whose m/z values correspond to y or b ions 
(some of which correspond to ions with the neutral loss of H3PO4 (-98)) are labeled.  The 
asterisk indicates the phosphorylated Ser1859 residue.  (C) The CAD residue Ser1859 was 
mutated to an alanine (S1859A) as described in Materials and Methods.  HEK-293 cells 
were transfected with either WT-Flag CAD or S1859A-Flag CAD and 2D-
phosphopeptide mapping was performed as in (A). The arrows indicate minor 
phosphopeptides. 
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Figure 2.3.  Identification of the CAD phosphopeptide 1769-1780.  (A) Peptides from 
spot three (Figure 2.2A.) were eluted off the cellulose from the TLC plate.  The peptides 
then were analyzed by MALDI-MS on a Bruker Daltonics Ultraflex mass spectrometer.  
The upper panel is the mass spectrum showing the peak at 1526.531 corresponding to the 
predicted m/z of the singly charged 1769ARWTPFEGQKVK1780 CAD peptide with the 
addition of one phosphate group.  The peptides then were treated with alkaline 
phosphatase on the MALDI plate and reanalyzed.  The mass spectrum of the phosphatase 
treated peptides (bottom panel) shows a peak at 1446.536, which is 80 (the m/z of a 
phosphate moiety) less than the 1526.531 peak in the upper panel.  Since Thr1772 is the 
only residue in this peptide able to be phosphorylated, we assigned this residue as a CAD 
phosphorylation site.  (B)  A sequence alignment using ClustalX was performed on CAD 
amino acid sequences from the indicated organisms.  The sequences that were used have 
the following NCBI Accession numbers:  Hamster (P08955); Human (P27708); C. 
elegans (NP_495838); Zebra fish (CAI20956); D. melanogaster (NP_523377); S.
cerevisiae (CAA89425). 
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Figure 2.4.  Phosphopeptide spot 2 is not one of the previously reported CAD 
phosphopeptides.  Phosphopeptide mapping (described in Materials and Methods) was 
performed on either WT-Flag CAD, or the indicated Thr/Ser to Ala mutants isolated from 
[32P]-orthophosphate labeled HEK-293 cells.
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Figure 2.5.  The Dephosphorylation of Flag-CAD from HEK-293 cells inhibits 
CPSase II activity.  (A) CAD was immunoprecipitated from [32P]-orthophosphate 
labeled HEK-293 cells.  CAD was then dephosphorylated with calf intestinal alkaline 
phosphatase (CIP) and separated by SDS-PAGE as described in Materials and Methods.  
CAD was visualized by staining the gel with Coomassie stain, and an autoradiogram was 
performed.  (B) The treatment of CAD with CIP was performed as in (A), and CAD was 
excised from the gel and 2D phosphopeptide mapping was performed as described in 
Materials and Methods.  (C) Immunoprecipitated Flag-CAD was incubated with CIP for 
the indicated times, and CPSase II activity with the presence of 20 mM ATP was 
measured as described in Materials and Methods.  The CPSase II activity at each time 
point is graphed as percent activity compared to the activity of CAD incubated without 
CIP under the same conditions (Materials and Methods).  (D) CPSase II assays of CAD 
treated with or without CIP were performed in the presence of 500 µM PRPP and 2 mM 
ATP.  The PRPP stimulation is plotted as percentage of total activity without added 
PRPP. 
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Figure 2.6.  PKA phosphorylates CAD on Ser1406 and Ser1859 in HEK-293 cells.  Flag 
CAD was immunoprecipitated from HEK-293 cells was incubated with or without the 
catalytically active PKA subunit and [-32P]ATP (A).  2D phosphopeptide mapping was 
performed on WT Flag-CAD (B and D) or S1406A Flag-CAD (C) immunoprecipitated 
from [32P]-orthophosphate labeled cells that were treated with either DMSO or 20 µM
forskolin for 15 min (B and C), or DMSO or 20 µM H89 for three hours (D). 
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Figure 2.7.  CAD was not significantly phosphorylated by ERK in HEK-293 Cells.  
Immunoprecipitated WT Flag CAD or T456A Flag-CAD was incubated with or without 
active ERK2 and [-32P]ATP and 2D phosphopeptide mapping was performed as 
described in Materials and Methods (A).  2D phosphopeptide mapping was performed on 
immunoprecipitated WT-Flag CAD (B, C, and D) or T456A Flag-CAD (D) from 
metabolically labeled HEK-293 cells that were stimulated with or without 150 ng/ml 
EGF for 15 min (B), or with 10 µM U0126 or DMSO for three hours (C).  Lysates from 
the unstimulated or EGF-stimulated (B) and the DMSO or U0126 (C) treated cells were 
separated by SDS-PAGE and ERK activity was measured by immunoblotting with an 
anti-phospho ERK antibody. 
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Figure 2.8.  Serum does not stimulate CAD phosphorylation.  2D phosphopeptide 
mapping was performed on immunoprecipitated Flag-CAD isolated from HEK-293 cells 
that had been grown in low serum media for 18 hours prior to being stimulated with 10 % 
fetal bovine serum (FBS) for the indicated times (described in Material and Methods).  
The arrows indicate minor phosphopeptide spots. 
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Figure 2.9.  The pThr456 antibody is not specific for this CAD phosphorylation site. 
Cells with low CAD activities (G9C), were induced to stably express the vector 
PCDNA3.1, WT-CAD, or T456A-CAD in a previous report (Graves et al., 2000).  G9C 
cells stably expressing WT-CAD, T456A-CAD, or PCDNA3.1 were lysed and separated 
into detergent soluble or insoluble as described in (Sigoillot et al., 2005).  SDS-PAGE 
was performed and immunoblots using the Santa Cruz anti-pThr456 antibody (A, bottom 
panel), or an anti-CAD antibody (A, top panel) were performed.  (B) WT Flag CAD (lane 
3) or T456A Flag-CAD (lanes 4) were immunoprecipitated from HEK-293 cells.  20 µg
of lysate from cells transfected with WT Flag-CAD (lane 1), or T456A Flag-CAD (lane 
2).  The proteins were analyzed by immunoblotting with the anti-pThr456 or anti-Flag 
antibodies as indicated. 
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Figure 2.10.  Forskolin treatment of HEK-293 cells causes a slight decrease both 
CPSase II activity and PRPP activation. HEK-293 cells were transfected with WT 
Flag-CAD and treated with the vehicle DMSO or 20 µM forskolin for 15 min prior to 
harvesting so that.  This treatment was observed to induce the phosphorylation of Ser1406 
in Figure 2.6.  Flag-CAD was immunoprecipitated and CPSase II activity assay were 
with varying concentrations of ATP (A), or 2 mM ATP and 500 µM PRPP (B).  The 
curves in (A) were generated using GraphPad Prism version 4.01 for Windows 
(GraphPAD Software, San Diego, CA, www.graphpad.com), by performing nonlinear 
regression analysis and fitting the raw data to the equation Y = Vmax * Xh/(K + Xh)
where h is the Hill coefficient and K is the apparent Km..  The PRPP stimulation is 
plotted as percentage of total activity without added PRPP (B). 
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Figure 2.11.  The effects of CAD phosphorylation site mutants on CPSase II activity 
and PRPP stimulation. (A) The CPSase II activity of the immunoprecipitated WT-Flag 
CAD, or the indicated Flag-CAD mutants, was measured at 2 mM. 5 mM, or 20 mM 
ATP as described in Materials and methods.  The curves were generated using GraphPad 
Prism version 4.01 for Windows (GraphPAD Software, San Diego, CA, 
www.graphpad.com), by performing nonlinear regression analysis and fitting the raw 
data to the equation Y = Vmax * Xh/(K + Xh) where h is the Hill coefficient and K is the 
apparent Km.  (B) CPSase II activity of WT-Flag CAD or the indicated Flag-CAD 
mutants was measured in the presence or absence of 500 µM PRPP with 2 mM ATP.  
The PRPP stimulation is plotted as percentage of total activity without added PRPP. 
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Figure 2.12.  The T1037A CAD mutant decreases CPSase II activity, but increases 
PRPP stimulation of CPSase II activity.  CPSase II activity was measured from 
immunoprecipitated WT-Flag CAD (square) or T1037A Flag-CAD (triangle) in the 
absence of PRPP with varying concentrations of ATP (A) or at 2 mM ATP in the 
presence of varying concentrations of PRPP (B). The curves in (A), were generated 
using GraphPad Prism version 4.01 for Windows (GraphPAD Software, San Diego, CA, 
www.graphpad.com), by performing nonlinear regression analysis to fit the raw data to 
the equations Y=Vmax * Xh/(K + Xh) where h is the Hill coefficient and K is the 
apparent Km.  The PRPP stimulation in (B) is plotted as percentage of total activity 
without added PRPP. 
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Figure 2.13.  Caffeine inhibits CAD phosphorylation on Ser1859. WT Flag-CAD was 
isolated from HEK-293 cells that were metabolically labeled with [32P]-orthophosphate 
and treated with or without 5 mM caffeine for 3 hours prior to harvesting.  2D 
phosphopeptide maps then were performed as described in Materials and Methods. 
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Figure 2.14.  14-3-3 interacts with Flag-CAD from HEK-293 cells, but does not 
require the CAD phosphorylation site Ser1406. Lysates from PCDNA3.1, WT Flag-
CAD, or S1406A Flag-CAD vector transfected cells   were incubated with either GST-
conjugated, or GST-14-3-3 conjugated glutathione beads.  SDS-PAGE was performed 
and Flag-CAD was detected by immunoblotting with the anti-Flag antibody. 
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CHAPTER III 
 
THE HUMAN RAD9 CHECKPOINT PROTEIN STIMULATES THE CARBAMOYL 
PHOSPHATE SYNTHETASE ACTIVITY OF THE MULTIFUNCTIONAL PROTEIN 
CAD 
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3.1    Introduction 
The human Rad9, Rad1, and Hus1 proteins make a PCNA-like 
heterotrimericcomplex that has a ring structure and is thought to play a PCNA-like role as 
a DNA clamp specific for the DNA damage checkpoint response (reviewed in (Sancar et 
al., 2004)). It has been found that the checkpoint specific Rad17-RFC specifically binds 
to the 9-1-1 complex and clamps it around a DNA duplex (Bermudez et al., 2003; Ellison 
and Stillman, 2003; Majka and Burgers, 2003; Zou et al., 2003).  Although the precise 
mechanism by which the Rad17-RFC/9-1-1 complex clamp loader/checkpoint clamp 
senses damage and initiates cell cycle arrest is not known, significant progress has been 
made in understanding the role of this complex. 
Investigations into how the 9-1-1 complex may transduce a signal to downstream 
proteins in the checkpoint response have revealed that subunits of the complex, in 
particular Rad9, interact with a number of other cellular proteins with no obvious role in 
cell cycle arrest and have raised the possibility that these proteins might individually 
participate in other cellular functions as well. For example, Rad9 has recently been 
shown to bind to the androgen receptor and modulate its activity (Wang et al., 2004). 
Rad9 also binds to the kinases c-Abl (Yoshida et al., 2002) and PKCZ (Yoshida et al., 
2003), which in turn regulate the binding of Rad9 to the antiapoptotic proteins Bcl-2 and 
Bcl-xL, suggesting that Rad9 may play a role in the apoptotic response to genotoxic stress 
(Komatsu et al., 2000). 
In the course of our studies on the function of the 9-1-1 complex, we found that 
when Rad9 was purified by immunoaffinity chromatography from extracts of transiently 
transfected human cells, the purified Rad9 preparation contained a protein of 240 kDa as 
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a major contaminant. Mass spectrometric analysis was used to identify this protein as 
carbamoyl phosphate synthetase/aspartate transcarbamoylase/dihydroorotase (CAD), a 
multienzymatic protein that catalyzes the first three steps in de novo pyrimidine synthesis 
(Jones, 1980). The rate-limiting step in this pyrimidine synthesis pathway is catalyzed by 
the carbamoyl phosphate synthetase II (CPSase) of CAD, which is also the site of 
feedback inhibition by uridine nucleotides and activation by the allosteric ligand 
phosphoribosyl pyrophosphate (PRPP) (Carrey and Hardie, 1988). CPSase activity is 
increased in tumor cells (Reardon and Weber, 1985; Sigoillot et al., 2004) and is reported 
to be regulated by the protein kinase A and mitogen-activated protein kinase signaling 
pathways in a growth- and cell cycle-dependent manner (Graves et al., 2000; Huang and 
Graves, 2003; Sigoillot et al., 2003; Sigoillot et al., 2002a). We find that Rad9 binds to 
the CPSase domain and that this binding results in a two-fold stimulation of the CPSase 
activity of CAD. This is the first documented report of a protein-protein interaction with 
CAD regulating its CPSase activity. We find that CAD interacts with free Rad9, but not 
Rad9 within the 9-1-1 checkpoint complex. These findings suggest that Rad9 may have 
an additional role to its checkpoint function in ribonucleotide biosynthesis. 
3.2    Experimental Procedure 
3.2.1    Materials 
Antisera that recognize various antigens were obtained as follows: rabbit anti-His6
(H-15) and rabbit anti-hRad9 (M-389) from Santa Cruz Biotechnology (Santa Cruz, CA), 
mouse anti-Flag from Sigma (St. Louis, MO). 
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3.2.2     Transfections and immunoprecipitations 
 Human embryonic kidney 293T cells were grown in Dulbecco’s modified 
Eagle’s medium (Gibco BRL) supplemented with 10% fetal bovine serum, 100 U of 
penicillin and streptomycin per ml and were transfected with pcDNA3-FlaghRad9, 
pcDNA3-His6FlagCAD, pcDNA3-His6FlagCPSII, or pcDNA3-HA-hRad9 plasmids 
using the calcium phosphate transfection method as previously described (Lindsey-Boltz 
et al., 2001). Forty-eight hours after transfection, cells were washed with PBS and lysed 
in 20 packed cell volumes of Lysis Buffer (50 mM Tris-HCl (pH 7.5), 0.3 M NaCl, 0.5% 
Nonidet P-40 (NP-40), protease inhibitors (Roche Molecular Biochemicals). After 
incubating 15 minutes on ice, the cell lysate was centrifuged for 30 min at 32,000 x g. 
The supernatant was incubated with anti-Flag agarose (Sigma) (20 µl/ml of lysate) for 4 h 
at 4°C. The resin was then washed twice with Lysis Buffer, twice with TBS (50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl), and the protein was eluted for 30 minutes at 4°C with 
TBS containing 0.2 mg/ml Flag peptide (Sigma). 
3.2.3     Expression and purification of recombinant proteins  
Baculoviruses were previously described for expression of full length Flag-Rad9, 
fragments of Rad9, and His6-CAD. Monolayer High Five insect cells (Invitrogen) were 
infected with either theHis6-CAD baculovirus alone or together with the Flag-Rad9 
baculovirus and then harvested after 48 hours. The cells were washed with PBS and lysed 
in 20 packed cell volumes of lysis buffer (50 mM Tris-HCl (pH7.5), 300 mM NaCl, 15 
mM imidazole, 0.5% Nonidet P-40 (NP40), and protease inhibitors). After incubating 15 
minutes on ice, the cell lysate was centrifuged for 30 min at 32,000 x g. The supernatant 
was incubated with Ni-NTA agarose (Qiagen) (50 µl/ml of lysate) for 4 hours at 4°C. The 
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resin was then washed twice with lysis buffer, twice with elution buffer (50 mM Tris-HCl 
(pH 7.5), 10% glycerol, 0.3 M NaCl, 2 mM ATP), and then eluted with two volumes of 
elution buffer containing 100 mM imidazole. 
3.2.4    Interactions between CAD and Rad9, 9-1-1, and Rad9 fragments 
H5 insect cells were coinfected with baculoviruses expressing either His-CAD 
alone or together with either Flag-Rad9, or Flag-Hus1 and His-Rad1, or Flag-Hus1 and 
His-Rad1 and untagged Rad9, or the five fragments of Rad9 which were all previously 
described (Bermudez et al., 2003). After lysing the cells in 50 mM Tris-HCl (pH 7.5), 0.3 
M NaCl, 0.5% NP40, the protein was then immunoaffinity purified using anti-Flag 
agarose. After washing the resin three times in the same buffer, the protein was eluted 
with Flag peptide and analyzed by western blotting. 
3.2.5    CPSase activity assay  
CPSase activity was measured essentially as described previously (Huang et al., 
2002).  Briefly, all of the reaction components except the cold and 14C-labeled sodium 
bicarbonate (the initiation solution) were added to tubes on ice. These samples then were 
placed in a 37°C water bath for 10 minutes before the initiation mix was added to start 
the reaction. The 250 µl reaction was allowed to proceed for 30 minutes at 37°C before it 
was quenched by the addition of 125 µL of 80 % trichloroacetic acid. The unincorporated 
14C then was removed by gently heating the samples at 85° C for 2-3 hours. The 
incorporation of 14C into the acid stable carbamoyl aspartate was then measured by 
scintillation counting. The reaction mixture, contained 7.5 µl of the elution buffer 
previously described containing approximately 0.11 µg of CAD, 87 mM Tris-HCl (pH 
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8.0), 87 mM KCl, 6.5% dimethyl sulfoxide, 2.2% glycerol, 0.87 mM dithiothreitol, 3.1 
mM glutamine, 17.4 mM aspartate, 7 mM [14C]NaHCO3 (50 mCi/mmol), 2 mM excess of 
MgCl2 over the addition of nucleotide and PRPP concentrations, and ATP concentrations 
(adjusted to ATP contained within the protein elution buffer) varying from 0.06 mM to 
15 mM. 
3.3    Results 
3.3.1    Copurification of CAD with Rad9 
 In the course of our studies on the 9-1-1 complex, we found that when HEK293T 
cells were transfected with a plasmid expressing Flag-tagged Rad9 and the protein was 
purified with anti-Flag agarose, the preparation contained a major band of 240 kDa and a 
minor band of 110 kDa. These bands were not seen in immunoaffinity-purified extracts 
from control cells transfected with vector alone (Figure 3.1). Mass spectroscopic analysis 
of Rad9-copurifying bands revealed that the 240 kDa protein is CAD and the 110 kDa 
protein is the heat shock protein hsp110. As heat shock proteins often co-purify with 
ectopically expressed proteins, we concentrated our efforts on characterizing CAD, the 
major protein that copurifies with Rad9. 
3.3.2    Mapping of CAD and Rad9 Domains Required for Binding 
The human CAD protein catalyzes three separate reactions with three distinct 
structural domains, carbamoyl phosphate synthetase II (CPSase), aspartate 
transcarbamoylase (ATCase), and dihydroorotate reductase (DHOase) (Figure 3.2a). 
Similarly, human Rad9 has an N terminal PCNA-like domain and a C-terminal extension, 
which is heavily phosphorylated and is thought to play a role as an effector in checkpoint 
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signaling (Roos-Mattjus et al., 2003; St Onge et al., 2001; St Onge et al., 2003) (Figure 
3.2b). To gain insight into the potential physiological significance of the CAD-Rad9 
interaction, we mapped the interacting regions on both proteins by deletion analysis. In 
Figure 3.3, both full-length CAD and the CPSase domain of CAD were co-expressed 
with Rad9 in 293T cells and the CAD and CPSase immunoprecipitates were 
immunoblotted for Rad9. As seen in Figure 3.3 (right panel), Rad9 bound equally well to 
the full-length CAD and to the CPSase domain alone. To perform reciprocal experiments, 
insect cells were infected with baculoviruses expressing CAD together with regions of 
Rad9. The Rad9 fragments were immunoprecipitated and the precipitates were analyzed 
for CAD by immunoblotting. As seen in Figure 3.4, the N-terminal and the middle third, 
but not the C terminal third of Rad9 bound to CAD. The strongest binding was observed 
with the N terminal two-thirds of the protein. Interestingly, the C-terminal two-thirds 
bound CAD with less affinity than the middle third alone, suggesting that the C-terminal 
tail may negatively regulate the Rad9-CAD interaction. While the quantitative aspects of 
the data regarding the binding strength has certain limitations, this data unambiguously 
show that the PCNA-like domain of Rad9 binds to CAD whereas the C-terminal domain, 
which encompasses the major Rad9 phosphorylation sites and presumably acts as an 
effector in checkpoint signaling, does not. 
3.3.3     CAD Binds to Free Rad9 But Not to Rad9 Within the 9-1-1 Complex 
 To investigate whether CAD may participate in Rad17-RFC/9-1-1 complex-
mediated signal transduction, we tested the binding of CAD to the other members of the 
9-1-1 complex, Rad1 and Hus1, as well as to the ternary Rad9-Rad1-Hus1 complex by 
co-infection of insect cells with combinations of baculoviruses that express these 
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proteins. The tagged 9-1-1 proteins were immunoprecipitated and the immunoprecipitates 
were tested for the other 9-1-1 proteins and for CAD. Figure 3.5 shows that Rad9 
expressed in insect cells, like Rad9 expressed in mammalian cells, binds CAD, but Rad1 
and Hus1 do not (lane 1 vs. lane 2). Most significantly, when Rad9 is co-
immunoprecipitated as part of the 9-1-1 complex by using a Hus1 affinity tag, the 
immunoprecipitate does not contain any detectable CAD (lane 3). This was somewhat 
expected because Rad9 interacts with Rad1 and Hus1 through its PCNA-like domain 
suggesting that this domain is apparently blocked from binding to CAD within the 9-1-1 
complex. These findings suggested that the Rad9-CAD interaction might have a role in 
cellular physiology other than DNA damage checkpoint signaling. 
3.3.4    Modulation of Carbamoyl Phosphate Synthetase Activity 
Since currently there is no specific assay for Rad9 activity, we tested for the 
possible modulation of CAD activity by Rad9 in the following series of experiments. 
Initially, we found that immunoaffinity purified Rad9-CAD complex exhibited higher 
CPSase activity than CAD alone (data not shown). To further examine the effect of Rad9 
on CAD activity, we examined whether purified proteins could be combined to 
recapitulate this regulation. However, when combined in vitro, the two proteins did not 
form a stable complex, and we observed no change in the CPSase activity of CAD (data 
not shown). We reasoned that the two proteins may have to be co-expressed to form a 
complex, and therefore expressed CAD alone and CAD plus Rad9 in insect cells and 
purified these recombinant proteins using the His6 tag on CAD for affinity purification. 
We obtained the protein preparations shown in Figure 3.6. The CAD protein levels 
obtained under the two conditions were quite similar, and the amount of CAD activity 
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was normalized to the amount of CAD protein in each sample as determined by 
quantitative western analysis. CPSase synthesizes carbamoyl phosphate from ATP, 
bicarbonate, and glutamine, and is the first enzymatic step in pyrimidine biosynthesis. 
CPSase is allosterically activated by phosphoribosyl pyrophosphate (PRPP) and inhibited 
by UTP (Jones, 1980). We tested the effect of Rad9 on CPSase activity in the presence of 
saturating amounts of PRPP with varying ATP concentrations. We observed that the 
Vmax of CAD was increased two-fold by Rad9 both in the presence or absence of PRPP 
(Figure 3.7 and Table 3.1). Kinetic analysis of CAD/Rad9 complexes revealed that Rad9 
did not significantly change the apparent affinity for ATP (Km) in the presence or 
absence of PRPP. Likewise, a fragment of Rad9 lacking the C-terminal phosphorylation 
sites (fragment C in Figure 3.4) had a similar effect on the CPSase activity of CAD 
(Figure 3.7 and Table 3.1). Thus, it appears that Rad9 regulates the rate-limiting step of 
ribonucleotide biosynthesis by increasing the Vmax of the CPSase activity.   
 
3.4    Discussion 
Induction of ribonucleotide reductase (RNR) is one of the best characterized 
transcriptional response reactions to DNA damage and has been observed in organisms 
ranging from Escherichia coli to humans (Elledge et al., 1993). The upregulation of RNR 
activity by either transcriptional or post-transcriptional means increases the dNTP pools, 
and it has been shown that an increase in dNTP levels following DNA damage increases 
cellular survival in budding yeast (Chabes et al., 2003). Since rNTP pools are typically 
100-fold higher than the dNTP pools, it has generally been assumed that changes in rNTP 
levels would not affect the dNTP pool and hence survival and mutation rate. This 
assumption, however, has not been experimentally tested. Furthermore, RNA synthesis, 
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which would be affected by rNTP levels, might contribute to cellular recovery from 
genotoxic stress. Such an outcome of a Rad9-CAD interaction would place this 
interaction within the general DNA damage response network. However, it is also 
plausible that the Rad9-CAD interaction is operational under physiological conditions to 
maintain cellular homeostasis and that this function is not related to the checkpoint 
function of Rad9 which occurs within the context of the 9-1-1 complex. Indeed, Rad9 has 
been found to associate with a number of proteins with diverse functions some of which 
are not related the DNA damage checkpoint response. Additionally, de novo pyrimidine 
biosynthesis is not only important in dividing cells for the production of new nucleic 
acids, but also for UDP-sugars and CDP-lipids, which are used for diverse cellular 
functions (reviewed in Huang and Graves, 2003). Therefore, the Rad9-induced increase 
in CAD activity could be important in many different areas of cell physiology.   
We currently do not know the cellular location of the CAD-Rad9 interaction. 
While CAD is mainly cytoplasmic, some studies have provided evidence for a fraction of 
CAD being in the nucleus (Angeletti and Engler, 1998; Carrey et al., 2002; Sigoillot et 
al., 2003).  Under normal cellular conditions, Rad9 is part of the nuclear 9-1-1 complex 
(Burtelow et al., 2000; Burtelow et al., 2001). However, Rad9 does appear to have an 
independent cytoplasmic function during apoptosis. It has been demonstrated that during 
apoptosis Rad9 is cleaved by caspase-3 and the N-terminal portion of Rad9 translocates 
to the cytosol where it interacts with Bcl-xL (Lee et al., 2003). Since CAD does not 
associate with the 9-1-1 complex (Figure 3.5), and all detectable nuclear Rad9 is in this 
complex (Burtelow et al., 2001), it is likely that the CAD-Rad9 interaction takes place in 
the cytoplasm. 
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CAD is a unique biosynthetic enzyme with three distinct enzymatic activities.  
The CPSase enzyme domain catalyzes the formation of carbamoyl phosphate from 
glutamine, bicarbonate, and two molecules of ATP. The ATCase region catalyzes the 
synthesis of carbamoyl aspartate from aspartate and carbamoyl phosphate. Finally, the 
formation of dihydroorotate is catalyzed by the DHOase domain (Carrey and Hardie, 
1988). The assay used in these studies to measure CPSase activity is a coupled enzyme 
assay, which measures the incorporation of [14C] into the acid stable chemical carbamoyl 
aspartate, which, as mentioned above, is catalyzed by the enzymatic activities of both the 
CPS II and ATC domains. However, since the CPSase activity is rate limiting (reviewed 
in (Jones, 1980), the observed changes in enzymatic activity are most likely due to 
changes in the CPSase activity of CAD. 
The CPSase activity of CAD is highly regulated. As mentioned previously, it is 
allosterically activated by PRPP and inhibited by the product of pyrimidine-nucleotide 
synthesis, uridine 5‘-triphosphate (UTP). Moreover, phosphorylation can affect the 
allosteric regulation by PRPP and UTP An additional level of regulation of CPSase 
activity is by protein degradation induced by caspase 3 (Huang et al., 2002). The findings 
reported in this study add a previously unknown mode CPSase activity regulation. Our 
data reveal the first documented report that a protein-protein interaction with CAD can 
regulate CPSase activity. Although allosteric regulators (i.e. PRPP and UTP) decrease the 
Km for a CPSase substrate (ATP), our data suggests that Rad9 increases the Vmax of 
CPSase rather than changing the Km for ATP. Rad9 binding was also observed to 
increase the maximum velocity of CPSase activity in the presence of PRPP, but did not 
affect the percent activation by PRPP. We investigated the affect of Rad9 on UTP 
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induced inhibition of CPSase activity. Rad9 did not significantly decrease the inhibitory 
action of UTP, but this result varied between CAD protein preparations preventing us 
from making a conclusion from this data (data not shown). 
The mechanism by which Rad9 increases CPSase activity is not known. Rad9 
binding could increase the affinity of other CPS II substrates such as glutamine or 
bicarbonate. Another plausible hypothesis is that Rad9 increases the glutaminase activity 
of CPS II, thereby increasing the overall Vmax without affecting the affinity for ATP. 
However, this appears unlikely since experiments using ammonia as the nitrogen donor, 
thereby bypassing the need for the glutaminase activity, have shown that Rad9 still 
induced a two-fold increase in CPSase activity (data not shown). Alternatively, Rad9 
binding may induce a conformational shift that affects the oligomeric (activated) form of 
the enzyme. Active CAD has been shown to be a hexamer (Qiu and Davidson, 2000), and 
Rad9 may increase CAD activity by increasing the amount of enzyme in the hexameric 
form. Dissociation of CAD to monomers did not affect the CPSase activity, but 
significantly reduced the Vmax of ATCase (Qiu and Davidson, 2000). It is therefore 
possible that Rad9 could be increasing CAD activity by stabilizing the oligomeric form 
of this enzyme and thereby increasing the Vmax of ATCase. However, this seems 
unlikely since the CPSase activity of CAD is the rate limiting step (Jones, 1980), and an 
increase in the ATCase rate would not be expected to increase the overall rate of our 
coupled enzyme reaction. 
In summary, we find that the checkpoint protein Rad9 specifically interacts with 
the CPSase domain of CAD and increases its Vmax by at least a factor of two. The high 
specificity of the Rad9-CAD interaction strongly suggests that it is of significance to 
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normal cellular homeostasis. Further work is needed to determine the potential role of 
this interaction in regulating DNA damage checkpoints, ribonucleotide pools, or RNA 
and DNA synthesis. 
104
Figure 3.1.  Copurification of CAD with Rad9.  Copurification of CAD with Rad9.  An 
aliquot of 3 X 106 293T cell were mock treated (-) or transfected with 6 µg pcDNA3-
Flag-hRad9 (+).  Protein was immunoprecipitated using anti-Flag agarose from whole 
cell extracts, and 10 % of the protein eluted with Flag peptide was visualized after SDS-
PAGE by silver staining.  Mass spectrometric analysis was performed by the University 
of North Carolina Mass Spectrometry Core Facility. 
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Figure 3.2  Structural organization of CAD and Rad9. (A) The human CAD protein 
has three distinct structural domains performing the three enzymatic activities, carbamoyl 
phosphate synthetase (CPS II), aspartate transcarbamoylase (ATC) and dihydroorotase 
(DHO). The CPS II domain is indicated with gray shading. (B) Human Rad9 has an N-
terminal PCNA-like domain (gray shading) and a heavily phosphorylated C-terminal 
domain. 
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Figure 3.3.  Rad9 interacts with the CPSII domain of CAD.  An aliquot of 3· 106 293T 
cells was transfected with 6 mg of pcDNA3-HA-Rad9 alone (lane 1) or along with 6 mg 
of pcDNA3-Flag-CAD (lane 2), or pcDNA3-Flag-CPSII (lane 3).  The proteins were 
immunoprecipitated with anti-Flag agarose and then analyzed by western blotting with 
anti-Rad9 and anti-Flag antibodies as indicated. 
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Figure 3.4.  CAD interacts with the PCNA-like domain of Rad9. Insect cells were 
infected with His-CAD alone (-) or together with Flag-tagged fragments of Rad9 
(fragment A contains amino acids 1–130, fragment B contains amino acids 130–270, 
fragment C contains amino acids 1–270, fragment D contains amino acids 260–391 and 
fragment E contains amino acids 130–391) or with full-length Rad9 (F). The proteins 
were immunoprecipitated with anti-Flag agarose and then analyzed by western blotting 
with anti-His and anti-Flag antibodies as indicated. 
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Figure 3.5.  CAD binds to free Rad9, but not to Rad9 within the 9-1-1 complex. 
Insect cells were co-infected with His-CAD together with Flag-Rad9 (lane 1), or Flag-
Hus1 and His-Rad1 and untagged-Rad9 (lane 3).  The proteins were immunoprecipitated 
with anti-Flag agarose and then analyzed by western blotting with anti-His, anti-Rad9, 
and anti-Flag antibodies as indicated. 
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Figure 3.6.  Purification of CAD with and without Rad9. Insect cells were infected 
with His-CAD alone or together with Flag-Rad9. The proteins were affinity purified with 
Ni-agarose and then analyzed by Coomassie staining (left panel) and western blotting 
(right panels). The arrow indicates the position of CAD. Aliquots of 2.5, 5, 10 ml from 
each sample was loaded which correlates to ~50, 100, 200 ng of CAD and 25, 50, 100 ng 
of Rad9 when quantitated using protein standards in the same gel. 
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Figure 3.7.  Rad9 increases the CPSase Vmax.  CPSase activity was measured from 
purified CAD (square) expressed alone or co-expressed with full-length Rad9 (triangle) 
or Rad9 with a C-terminal deletion (upside-down triangle) in the absence (A) or presence 
(B) of 2mM PRPP with varying concentrations of ATP. The CAD and CAD/Rad9 data 
represent pooled results from five separate experiments, while the data from the 
CAD/Rad9 fragment C represent pooled data from two separate experiments. The curves 
were generated using GraphPad Prism version 4.01 for Windows (GraphPad Software, 
San Diego, CA, www.graphpad.com) by performing nonlinear regression analysis to fit 
the raw data to the equation Y = Vmax * Xh/(K + Xh) where h is the Hill coefficient (set 
to 2) and K is the apparent Km. 
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Table 3.1.  Kinetic parameters of wild type CAD and CAD coexpressed with Rad9 
and Rad9 fragment C.  The kinetic parameters of the CPSase data from CAD and 
CAD/Rad9 represent pooled data from 5 separate experiments, while the data from the 
CAD/Rad9 fragment represents pooled data from 2 separate experiments. Km (mM ATP) 
is the apparent affinity for ATP, and Vmax (pmol•min-1) is the maximum CPSase 
velocity measured as a function of ATP concentration. These data are the numerical 
results from the graphs in Figure 4.7. 
 
CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
113
The studies in this dissertation were designed to investigate the regulation of CAD 
by phosphorylation and protein-protein interactions.  While numerous studies on CAD 
phosphorylation have been performed, my work is the first comprehensive study of CAD 
phosphorylation.  My data in Figure 2.7 demonstrated that CAD was not phosphorylated 
in response to ERK activation in HEK-293 cells, and thereby challenges the current 
dogma that the ERK-induced phosphorylation of CAD on Thr456 causes an increase in 
CAD activity and a consequent increase in intracellular pyrimidines (reviewed in (Evans 
and Guy, 2004).  Furthermore, while we observed that CAD is phosphorylated on Ser1406 
by PKA activation in HEK-293 cells, we did not detect the autophosphorylation at 
Thr1037, as was proposed in (Sigoillot et al., 2002a).  We discovered a previously 
unidentified CAD phosphorylation site contained in phosphopeptide spot three (Thr1772)
(Figure 2.3), but unfortunately were unable to determine the identity of the 
phosphopeptide in spot 2 on our 2D-phosphopeptide maps.  However, by the process of 
elimination, we determined that it did not contain one of previously reported CAD 
phosphorylation sites (Olsen et al., 2006; Sigoillot et al., 2002a; Sigoillot et al., 2002b). 
 One of our aims was to elucidate the effect of CAD phosphorylation on enzymatic 
activity and allosteric regulation.  CPSase II assays were performed on Flag-CAD 
immunoprecipitated from HEK-293 cells.  While this method of CAD isolation does not 
give the purity of CAD that other methods might provide, the specific activity of CPSase 
II from CAD isolated using our method was similar to previously reported CPSase II 
specific activities (Shaw and Carrey, 1992; Sigoillot et al., 2002a).  Therefore, this 
suggests that our method of CAD isolation and our CPSase II activity assays are valid. 
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As described above, we observed that CAD was phosphorylated on multiple 
residues in HEK-293 cells.  To determine if the phosphorylation of CAD was important 
for the enzymatic activity, we compared CPSase II activity between Flag-CAD treated 
with or without alkaline phosphatase.  As seen in Figure 2.5, the dephosphorylation of 
CAD significantly reduced CPSase II activity.  Furthermore, CAD is phosphorylated 
during the 3-4 hours of [32P]-orthophosphate labeling, and treatment of cells with the 
phosphatase inhibitor calyculin A caused a robust increase in the phosphorylation of 
phosphopeptides 1-4 (data not shown).  Therefore, this dynamic regulation of CAD 
phosphorylation and the importance of CAD phosphorylation for enzyme activity, 
suggests that this post-translational modification is an important mechanism by which 
cells regulate CPSase II activity. 
While the phosphatase treatment of CAD reduced the phosphorylation of 
phosphopeptides 1-4 (Figure 2.5B), we currently do not know if the dephosphorylation of 
one of these peptides is responsible for the reduction in CPSase II activity observed in 
Figure 2.5 C.  Since spots 1 and 4 contain pSer1859 (Figure 2.2) and the phospho-null 
mutant S1859A did not affect CPSase II activity, the dephosphorylation of Ser1859 
probably did not account for the decrease of CPSase II activity after phosphatase 
treatment.  However, whether the dephosphorylation of phosphopeptide spot 3, which 
putatively contained pThr1772, or phosphopeptide spot 2, accounted for the decrease in 
CPSase II activity remains to be tested.  Therefore, it will be important to determine the 
identity of phosphopeptide spot 2, so that a phospho-null mutation can be created to test 
the affect on CPSase II activity.  In addition, to conclusively prove that Thr1772 is the 
CAD phosphorylation site in phosphopeptide spot 3, and to know if the phosphorylation 
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of this site is important for CPSase II activity, we will need to create the T1772A mutant 
and perform 2D phosphopeptide mapping and CPSase II activity assays. 
The mechanism by which CAD phosphorylation regulates CPSase II activity is 
not known.  Since the functional unit of CAD in cells is a hexamer (Coleman et al., 1977; 
Lee et al., 1985; Qiu and Davidson, 2000), it is possible that the phosphorylation of CAD 
plays a role in the formation or maintenance of the hexamer.  Although the crystal 
structure of CAD has not been solved, phosphorylation may influence inter- or intra- 
CAD protein domain contacts.  Since the ATCase and DHOase regions appear to 
facilitate the CAD hexamer formation (Carrey, 1993; Qiu and Davidson, 2000), and the 
phosphorylation site Thr1772 is contained in the DHOase domain (Figure 1.6), the 
phosphorylation of this residue may play a role in hexamer formation.  To test this 
hypothesis, we could purify the T1772A CAD mutant from HEK-293 cells and perform 
glycerol gradient ultracentrifugation to determine if CAD hexamer formation was 
inhibited. 
While the identity of the kinase(s) that phosphorylated phosphopeptide spots 1-4 
in HEK-293 cells is unknown, our data suggested that phosphopeptide spot 5 (Ser1406)
was phosphorylated by PKA in HEK-293 cells (Figure 2.6).  Tatibana and colleagues 
first observed that the PKA-induced phosphorylation of CAD in vitro caused a slight 
increase in CPSase II activity.  Carrey and colleagues determined that PKA 
phosphorylated CAD in vitro on Ser1406 and Ser1859. Furthermore, they reported that the 
most significant effect of the phosphorylation of CAD by PKA was the reduction in the 
UTP-induced decrease in CPSase II activity.  Subsequent studies demonstrated that CAD 
was phosphorylated in intact cells after the stimulation of PKA activity.  While these data 
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suggested that the role of PKA-induced CAD phosphorylation was the activation of 
CPSase II activity, Evans and colleagues reported data that suggested that the PKA 
phosphorylation of CAD caused an overall decrease in CPSase II activity by decreasing 
the affinity for PRPP.  Furthermore, it was proposed that PKA caused a decrease in CAD 
activity and total cellular pyrimidines as cells became quiescent or as cells progressed 
through the cell cycle after S-phase.  To specifically determine if the phosphorylation of 
CAD by PKA in HEK-293 cells affected CAD activity, we stimulated HEK-293 cells 
with forskolin.  We observed a significant increase in Ser1406 phosphorylation (Figure 2.6 
B).  The CPSase II activity assays, performed on Flag-CAD treated under these same 
conditions, demonstrated that PKA activation caused only a slight reduction in CPSase II 
activity and PRPP activation.  Whether or not this slight reduction in enzymatic activity 
affects cellular pyrimidine synthesis remains to be tested.  Since forskolin is an extremely 
potent stimulator of cAMP synthesis, which strongly activates PKA, it is also 
questionable how physiologically relevant this regulation is. 
It is possible that the phosphorylation of Ser1406 by PKA serves a purpose other 
than modulating the acute CPSase II activity.  Since CAD has been found in the nucleus, 
and the phosphorylation of proteins can regulate nuclear entry, the phosphorylation of 
Ser1406 could regulate the nuclear entry of CAD.  Additionally, since the phosphorylation 
of CAD by PKA accelerated the cleavage of this multienzymatic protein by elastase and 
trypsin in vitro (Carrey and Hardie, 1988), the increase in CAD protein stability in cells 
may be a potential function for the PKA-induced phosphorylation of CAD. Interestingly, 
CAD protein is degraded during the differentiation of myoblasts into myocytes (Graves, 
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unpublished results).  It could be that the phosphorylation or dephosphorylation of CAD 
facilitates the degradation of this protein during differentiation. 
Additional studies have suggested that CPSase II activity is regulated by 
phosphorylation during cell cycle progression (Morford et al., 1994; Sigoillot et al., 
2002a).  While it is has been demonstrated that mitogen stimulation of human 
lymphocytes increased CPSase II activity (Ito and Uchino, 1973) and the CPSase II 
activity of rat hepatoma cells increased gradually over the G1 phase reaching a maximum 
in the S-phase of the cell cycle, whether or not this is due to CAD phosphorylation is not 
well established.  Since resting primary human lymphocytes express undetectable levels 
of CAD mRNA and protein and there is a strong correlation between the mitogen-
stimulated increase in CAD expression and the observed increase in CPSase II activity 
(Wauson unpublished observations and (Ito and Uchino, 1971).  Thus it is possible that 
the main mechanism for the increase in CPSase II activity during the initial cell cycle 
progression is mediated by the increased expression of CAD.  Interestingly, we observed 
that this increase in expression was blocked by U0126, the MEK-1 inhibitor (Eric 
Wauson unpublished results).  However, this increase in CAD expression might only 
occur during the entry into the cell cycle from a G0 state and the phosphorylation of CAD 
might be important in subsequent cell divisions.  Indeed, Guy and colleagues reported 
that the increase in PRPP stimulation of CPSase II activity and the decrease in UTP 
inhibition observed as the BHK 165-23 hamster cells proceeded through G1 and into S-
phase and correlated with an increase in threonine phosphorylation of CAD (Sigoillot et 
al., 2003). 
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To investigate the role of CAD phosphorylation in the cell cycle, it will be 
important to determine the identity of the specific CAD residues phosphorylated during 
specific cell cycle phases.  Therefore, phosphospecific antibodies that recognize pSer1406,
pThr1772, pSer1859, and the yet to be determined phosphorylated amino acid in spot 2, 
could be created.  Cells could be synchronized and the phosphorylation of each of the 
above residues could be examined at each stage of the cell cycle.  Additionally, the 
phosphorylation status of CAD from cancer cell lines that are known to have elevated 
CAD activity and/or de novo pyrimidine synthesis (Aoki et al., 1982a; Aoki and Weber, 
1981; Karle et al., 1986; Sigoillot et al., 2004), could be profiled using these 
phosphospecific antibodies.  Furthermore, the phosphorylation status of CAD from 
samples of primary cancer tissues could be investigated.  This specific phosphorylation of 
CAD could also be examined in cells in normal rapidly growing tissues, such as 
regenerating liver, spleen, testis, thymus, and mitogen-stimulated lymphocytes (Aoki et 
al., 1982b; Ito and Uchino, 1971; Yip and Knox, 1970).  These experiments would allow 
us to determine if there is a correlation between the phosphorylation of specific CAD 
residues and elevated CAD activity in numerous cell types.  Ultimately, this approach 
would allow us to gain a better understanding of the physiological role of CAD 
phosphorylation. 
To fully understand the role of CAD phosphorylation in cell physiology will 
require the identification of the kinase(s) that phosphorylate CAD.  While our data from 
Figure 2.6 indicate that PKA phosphorylates CAD on Ser1406 Ser1859, we do not know the 
kinase that phosphorylates Thr1772, or the residue in spot 2 (Figure 2.2).  Additionally, 
while our data suggests that ERK is not responsible for phosphorylating and regulating 
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the activity of CAD during the cell cycle as was reported (Sigoillot et al., 2003), there 
may be another kinase mediating the phosphorylation and activity of CAD during the cell 
cycle.  Therefore, a future direction would be to determine which kinase(s) is responsible 
for the phosphorylation of CAD during the cell cycle.  Since HeLa cells have been used 
extensively as a model to study cell cycle regulation, I propose to synchronize HeLa 
cells, release them into the cell cycle, and harvest them at multiple time points during the 
progression of the cell cycle.  Kinase assays would be performed to identify the lysate 
that contained a CAD kinase activity.  The lysate that contained a CAD kinase would be 
fractionated by size exclusion chromatography and kinase assays would be performed to 
find the fraction(s) that still contained a CAD kinase.  This fraction then would be 
separated using SDS-PAGE, and the gel would be silver-stained.  Since kinases 
autophosphorylate, autoradiography would be performed on the gel to identify potential 
kinases.  The protein bands then could be identified by mass spectrometry.  This method 
could allow us to identify putative cell cycle regulated kinase(s) that phosphorylated 
CAD.  Since we observed evidence that suggested there was a basally active kinase in 
HEK-293 cells that phosphorylated CAD (Chapter II), we could use this approach to 
identify the kinase in HEK-293 cells.  Finally, experiments using kinase inhibitors and 
RNAi designed to knockdown the putative CAD kinase(s) would be performed to 
determine if CAD was phosphorylated in intact cells by this kinase. 
A cell model where endogenous CAD is not expressed would be useful in 
deciphering the role of CAD phosphorylation.  The Chinese hamster ovary cell line that 
displays low levels of endogenous CAD activity (Musmanno et al., 1992) has been used 
in the past to test the function of CAD mutants (Banerjei and Davidson, 1997; Graves et 
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al., 2000).  However, since these cells were created by chemical mutagenesis, they likely 
have additional mutations that could confound the interpretation of results.  
Consequently, another cell model would be favorable.  Cells could be created that 
expressed siRNA that knocked-down WT-CAD expression.  These cells then could be 
transfected with various CAD phosphorylation site mutants, which would be designed to 
not be recognized by the siRNA.  The growth parameters, cell cycle progression, and 
intracellular pyrimidine levels would be tested in these cells to determine the effects of 
the phosphorylation site mutants on cell physiology.  Furthermore, as done in previous 
studies (Sigoillot et al., 2005), the effect of CAD phosphorylation on the flux of 
precursors through the de novo pyrimidine pathway could also be investigated. 
Another potential role of CAD phosphorylation may be the regulation of CPSase 
II activity during embryogenesis.  Since the half-life of CAD protein is at least 24 hours 
(reviewed in Huang and Graves, 2003), and CPSase II enzymatic activity fluctuates 
relatively rapidly during Drosophila development (Mehl and Jarry, 1978), it is possible 
that the phosphorylation and/or other post-translational modifications of CAD protein are 
responsible for these changes in CPSase II activity.  Furthermore, CAD expression is 
dynamically regulated during zebrafish embryogenesis, with CAD levels being high in 
the rapidly proliferating cells and low in tissues as cell growth slows and the cells exit the 
cell cycle.  CAD expression is particularly high in the developing zebrafish retina, and 
the knockdown of CAD mRNA during zebrafish embryogenesis causes retinal 
malformation (Willer et al., 2005).  In addition to CAD expression changes, the CPSase 
II activity during embryogenesis may be regulated by phosphorylation.  The 
phosphorylation status of CAD during zebrafish embryogenesis could be investigated by 
121
using phospho-specific CAD antibodies to perform immunohistochemistry on zebrafish 
embryos during different stages of embryogenesis. 
In addition to phosphorylation, the CPSase II activity of CAD can be regulated by 
the interaction with hRad9.  While we have demonstrated that hRad9 binds to CAD and 
this interaction increases enzymatic activity, future experiments are needed to determine 
the physiological role of this protein-protein interaction.  It is interesting to speculate that 
upon DNA damage, hRad9 may bind to CAD; thereby, inducing an increase in 
pyrimidine nucleotides that may be needed to repair damaged DNA.  Significant 
increases in cellular pools of deoxynucleoside triphosphates (dNTPs) in yeast have been 
observed to be necessary for survival after DNA damage induction.  However, an 
increase in cellular pools of ribonucleoside triphosphates (NTPs) did not appear 
necessary for the increase in dNTPs.  However, there are differences in how yeast and 
mammalian cells regulate their NTP and dNTP levels during normal cell cycle 
progression or following DNA damage.  Therefore, while it is known that NTP levels 
fluctuate during normal cell cycle progression in mammalian cells (Schobitz et al., 1991; 
Sigoillot et al., 2003), whether or not NTP levels increase after DNA damage induction 
or other cellular stresses needs to be tested.  Additionally, to determine if the hRad9/CAD 
interaction plays a role in mediating cellular pyrimidine NTP levels in cells, we could 
compare the rate of de novo pyrimidine synthesis and the concentrations of NTPs 
between the hRad9-/- and WT mouse embryonic stem cells (Hopkins et al., 2004). 
While it is not clear if the hRad9/CAD interaction is involve in the DNA damage 
response, other recent data has suggested that CAD may be involved in the DNA damage 
response.  For instance, CAD was found in a complex with the DNA damage 
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postreplicative mismatch repair enzyme PMS2 (Cannavo et al., 2007).  Additionally, we 
demonstrated that caffeine, which inhibits the DNA damage inducible kinases 
ATM/ATR, inhibited Ser1859 phosphorylation (Figure 2.13).  While ATM/ATR may not 
directly phosphorylate Ser1859, since it is not a consensus site for these kinases, the 
Chk1/2 kinases, which are activated by ATM/ATR, may phosphorylate this residue.  It is 
interesting to speculate that the role of the phosphorylation of Ser1859 by a caffeine 
sensitive DNA damage inducible kinase is to regulate the binding of CAD to either 
hRad9 and/or PMS2. 
 As discussed earlier, CAD either interacts with 14-3-3 directly, or with another 
protein that binds to 14-3-3. The 14-3-3 proteins are a family of proteins containing 
seven isoforms that exert biological functions by binding to client proteins.  The effects 
of the binding of 14-3-3 to client proteins are numerous and include, but are not limited 
to:  modulation of enzymatic activity, changes in subcellular localization, and protection 
against protein degradation (reviewed in Aitken, 2006).  Since we observed the CAD/14-
3-3 interaction in vitro (Figure 2.14), it will be important to determine if this interaction 
occurs in intact cells.  Experiments designed to determine the physiological role of the 
CAD/14-3-3 protein-protein interaction need to be performed.  Since most of the 14-3-3 
interactions occur at a phosphorylated residue, we would determine if one of the CAD 
phosphoamino acids mediates the CAD/14-3-3 interaction.  As we did with the S1406A 
Flag-CAD mutant (Figure 2.14), we will determine if any of the other phosphorylation-
null mutants prevent 14-3-3 binding.  Additionally, to determine if 14-3-3 binding 
affects CAD activity in HEK-293 cells, we could knockdown 14-3-3 in cells to 
determine how CAD activity is affected. 
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Furthermore, since 14-3-3 binding can affect protein stability (Aitken, 2006), we 
could investigate the half-life of CAD in cells that were devoid of 14-3-3 .
Interestingly, Kido and colleagues discovered that of 14-3-3 was significantly 
upregulated in Drosophila after heat stress.  Furthermore, they observed that 14-3-3
protected the enzyme citrate synthase against heat stress-induced inactivation.  Since 
CAD is known to be thermally unstable (Guy and Evans, 1994b), the CAD/14-3-3
interaction may function to facilitate CAD stability at elevated temperatures. 
In summary, we have performed a comprehensive analysis of CAD 
phosphorylation.  We have identified major phosphorylation sites in CAD isolated from 
HEK-293 cells that appear to be important for enzymatic activity.  Furthermore, we have 
shown that at least in HEK-293 cells, CAD is not phosphorylated in response to growth 
factor induced-ERK activation.  Therefore, the current proposal that ERK-induced 
phosphorylation of CAD is responsible for the increase in cellular pyrimidines needed for 
cellular growth should be reevaluated.  While we anticipated finding phosphorylation 
events that directly regulated CAD activity, our data suggests that phosphorylation may 
play a subtler role in stabilizing CAD activity.  While some of the mutations that we 
examined abolished or significantly lowered CPSase II activity, it is possible that these 
mutants simply impaired the catalytic function of the CPSase II or ATCase domains by 
affecting residues necessary for catalysis.  Future studies are needed to determine the role 
of CAD phosphorylation in cell physiology. Finally, we have discovered a novel protein-
protein interaction between hRad9 and CAD that causes an increase in CPSase II activity.  
Further studies will be required to elucidate the physiological role of the hRad9-CAD 
interaction. 
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